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GM-CSF Enhances Macrophage Glycolytic Activity In Vitro
and Improves Detection of Inflammation In Vivo
Parmanand Singh*1, Silvia González-Ramos*2, Marina Mojena2, César Eduardo Rosales-Mendoza2,3, Hamed Emami4,
Jeffrey Swanson4, Alex Morss4, Zahi A. Fayad5, James H.F. Rudd6, Jeffrey Gelfand7, Marta Paz-García2,
Paloma Martín-Sanz2,8, Lisardo Boscá†2,8, and Ahmed Tawakol†4
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Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; 5Translational and Molecular Imaging
Institute, Icahn School of Medicine at Mount Sinai, New York, New York; 6Division of Cardiovascular Medicine, University of
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18F-FDG accumulates in glycolytically active tissues and is known to
concentrate in tissues that are rich in activated macrophages. In this
study, we tested the hypotheses that human granulocyte-macrophage
colony-stimulating factor (GM-CSF), a clinically used cytokine, in-
creases macrophage glycolysis and deoxyglucose uptake in vitro
and acutely enhances 18F-FDG uptake within inflamed tissues such
as atherosclerotic plaques in vivo. Methods: In vitro experiments
were conducted on human macrophages whereby inflammatory
activation and uptake of radiolabeled 2-deoxyglucose was assessed
before and after GM-CSF exposure. In vivo studies were performed on
mice and New Zealand White rabbits to assess the effect of GM-CSF
on 18F-FDG uptake in normal versus inflamed arteries, using PET.
Results: Incubation of human macrophages with GM-CSF resulted
in increased glycolysis and increased 2-deoxyglucose uptake (P ,
0.05). This effect was attenuated by neutralizing antibodies against
tumor necrosis factor–α or after silencing or inhibition of 6-phospho-
fructo-2-kinase. In vivo, in mice and in rabbits, intravenous GM-CSF
administration resulted in a 70% and 73% increase (P , 0.01 for
both), respectively, in arterial 18F-FDG uptake in atherosclerotic an-
imals but not in nonatherosclerotic controls. Histopathologic anal-
ysis demonstrated a significant correlation between in vivo 18F-FDG
uptake and macrophage staining (R 5 0.75, P , 0.01). Conclusion:
GM-CSF substantially augments glycolytic flux in vitro (via a mech-
anism dependent on ubiquitous type 6-phosphofructo-2-kinase and
tumor necrosis factor–α) and increases 18F-FDG uptake within inflamed
atheroma in vivo. These findings demonstrate that GM-CSF can be
used to enhance detection of inflammation. Further studies should
explore the role of GM-CSF stimulation to enhance the detection of
inflammatory foci in other disease states.
Key Words: 18F-FDG-PET; glycolysis; GM-CSF; inflammation;
macrophage
J Nucl Med 2016; 57:1428–1435
DOI: 10.2967/jnumed.115.167387
PET, in combination with 18F-FDG, has been shown to be
useful for the identification of inflamed tissues. Over the past
few years, 18F-FDG PET/CT imaging has been put into increasing
clinical use to evaluate syndromes such as fever of unknown or-
igin, cardiac sarcoidosis (1,2), prosthetic valve endocarditis (3),
and infection of implanted devices (4). More recently, the use of
18F-FDG PET/CT as a research tool to characterize atherosclerotic
cardiovascular disease has been increasing. However, more wide-
spread use of 18F-FDG PET imaging of inflammatory foci has
been limited, in part because of the relatively modest signal (5).
Approaches to enhance 18F-FDG localization to inflamed tissues
could improve the clinical utility of 18F-FDG PET imaging of
inflammatory diseases.
Perhaps the most common chronic inflammatory disorder, ath-
erosclerotic cardiovascular disease, remains the leading cause of
mortality in the United States (6). Inflammation plays a pivotal
role in atherogenesis, plaque progression, and thrombotic compli-
cations (7). In particular, the pathogenesis of atherosclerosis in-
volves a myriad of immune mediators, with a well-accepted role
for macrophages (8). A substantial body of cellular physiology
literature has established that activated macrophages show upre-
gulated glycolysis and hence avidly accumulate 18F-FDG (5,9).
Key enzymatic mediators of macrophage activity include the glu-
cose transporters, the upper part of glycolysis, and specifically the
expression of the ubiquitous form of 6-phosphofructo-2-kinase
(PFKFB3), which has been noted to be upregulated in stimulated
macrophages (compared with the constitutively expressed liver
type-6-phosphofructo-2-kinase [PFKFB1] isoenzyme, which is as-
sociated with lower rates of glycolysis) (9). Advances in 18F-FDG
PET imaging have led to its use for the quantification of vascular
wall inflammatory activity. 18F-FDG uptake has been shown to
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strongly correlate with arterial wall macrophage infiltration (10),
systemic proinflammatory biomarkers (11), inflammatory cell gene
expression (12), and increased risk for subsequent atherothrombotic
events (13,14).
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
is a Food and Drug Administration–approved medication used to
stimulate the production of white blood cells and thus prevent
neutropenia after chemotherapy. It affects a wide range of immune
cells, including macrophages, neutrophils, and dendritic cells (15–18).
The drug is well tolerated, even among individuals with athero-
sclerosis or those with recent atherothrombotic events (19,20).
Accordingly, we sought to evaluate whether GM-CSF could be
used as an adjunctive agent to enhance the detection of inflamed
foci. Specifically, we performed both in vitro and in vivo experiments
to better understand the effect of GM-CSF on macrophage glycolytic
flux and on 18F-FDG uptake, which is dependent on glucose flux.
In these studies, we tested the hypotheses that GM-CSF augments
glycolytic flux in macrophages in vitro and enhances 18F-FDG
accumulation within inflammatory foci in vivo, thereby enhancing
imaging sensitivity.
MATERIALS AND METHODS
Cellular Experiments
Chemicals. Reagents and antibodies were from Sigma-Aldrich, Roche,
Invitrogen, R&D Systems, Santa Cruz Biotech, or Merck-Millipore.
[U-14C]-2-deoxyglucose (9,250 kBq [250 mCi]/mmol) was from New
England Nuclear/Perkin Elmer. Serum and media were from BioWhit-
taker. Murine and human GM-CSFs were from PeproTech or Gentaur.
Preparation of Human Monocytes/Macrophages. PBMCs were iso-
lated from the blood of healthy donors by centrifugation on Ficoll-
Hypaque Plus (GE Biotech) following the manufacturer’s protocol, and
the CD14-enriched fraction was collected after binding to MACS-hCD14-
magnetic beads (Miltenyi Biotec). Cells were differentiated with human
CSF-1 (20 ng/mL, PeproTech) for 5 d in RPMI1640 supplemented with
antibiotics and 10% fetal calf serum. After this period, the cells were kept
for 48 h in medium lacking CSF-1 and treated with the indicated stimuli.
The purity of all cultures was verified by CD141 staining; on average,
more than 95% of the cells were highly positive for this surface marker.
Tumor Necrosis Factor–a (TNF-a) Neutralization. The cells were
maintained in culture and, 1 h before GM-CSF challenge, were treated
with a 20 ng/mL concentration of anti-TNF-a neutralizing antibody
(R&D Systems) as previously described (9), using a mouse IgG as
control.
PFKFB3 Silencing in Macrophages. The cells were transfected
overnight with lipofectamine and a mixture of 3 different Silencer Select
predesigned silencer RNAs from Ambion/Invivogen, following the in-
structions of the supplier. Controls with scrambled (negative) RNAs were
used to ensure the specificity of the silencing.
Measurement of Radiolabeled Deoxyglucose Accumulation. To evalu-
ate 2-deoxyglucose uptake, the cells (6-cm dishes) were washed with
warm Dulbecco modified Eagle medium lacking glucose and incubated
with this medium containing 0.3 mM glucose and 92.5 kBq (2.5 mCi) of
[U-14C]-2-deoxyglucose for 60–90 s, following a previous protocol (21).
The reaction was stopped by rapid aspiration of the medium and addition
of 1 mL of ice-cold Dulbecco modified Eagle medium containing 10 mM
glucose and 0.1 mM phloretin. The cell layer was washed twice with ice-
cold phosphate-buffered saline, and the cells were resuspended in 1 mL of
0.1 M NaOH in 0.1% sodium dodecyl sulfate. A linear incorporation of
radioactivity was observed for at least 2 min by scintillation counting.
Preparation of Macrophage Extracts. The cell cultures were washed
twice with ice-cold phosphate-buffered saline and homogenized in 0.2 mL
of buffer containing 10 mM Tris-HCl, pH 7.5; 1 mM MgCl2; 1 mM
ethylene glycol tetraacetic acid; 10% glycerol; 0.5% CHAPS buffer
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate); 1 mM
b-mercaptoethanol; and 0.1 mM phenylmethylsulfonyl fluoride and a
protease inhibitor cocktail (Sigma). The extracts were stirred in a vortex
mixer for 30 min at 4C and centrifuged for 15 min at 13,000g. The
supernatants were stored at 220C. Protein levels were determined using
the Bio-Rad detergent-compatible protein reagent. All steps were per-
formed at 4C.
Western Blot Analysis. Samples of cell extracts containing equal
amounts of protein (30 mg per lane) were boiled in 250 mM Tris-HCl, pH
6.8; 2% sodium dodecyl sulfate; 10% glycerol; and 2% b-mercaptoethanol
and size-separated in 10%–15% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis. The gels were blotted onto a polyvinylidene
fluoride membrane (GE Healthcare) and processed as recommended
by the supplier of the antibodies against the following human antigens:
signal transducer and activator of transcription 5 (STAT5), P-STAT5, hexo-
kinase-1, hexokinase-2, PFK-1, PFKFB1, PFKFB3, glyceraldehyde 3-
phosphate dehydrogenase, and b-actin. The blots were developed by
ECL protocol (GE Healthcare), and different exposition times were
performed for each blot with a charge-coupled device camera in a
luminescent image analyzer (Molecular Imager; BioRad) to ensure
the linearity of the band intensities.
Measurement of TNF-a, Lactate, and Fructose-2,6-Bisphosphate
(Fru-2,6-P2). TNF-a was measured in the cell culture medium using
an ELISA kit (PeproTech). Lactate accumulation was also measured
in the culture medium as previously described (9,22). The intracellular
concentration of Fru-2,6-P2 was determined in cell extracts treated
with 0.1 mL of NaOH (50 mM at 80C) and heated at 80C for 10 min.
The metabolite was measured after the activation of the pyrophosphate-
dependent 6-phosphofructo-1-kinase activity following a previous proto-
col (9,22).
Real-Time Quantitative Polymerase Chain Reaction. 3-mo-old Apoe2/2
mice were fed for 2 wk with a high-fat diet and intraperitoneally
administered 37.5 mg/kg of GM-CSF on day 12. On day 14, they were
sacrificed and the whole aorta was cleaned to remove the adventitial fat
and connective tissue in the magnifying glass, always working over a
sheet of ice. The aortas were transferred to RNAlater RNA stabilization
reagent (QIAGEN) and then to dry ice. Aorta total RNAwas isolated by
homogenization in QIAzol (QIAGEN) by a Tissue Lyser LT (QIAGEN)
and eluted in a volume of 15 mL using MinElute columns (QIAGEN).
RNA integrity was assessed by RNA 6000 Nano Kit (Agilent). A 250-ng
quantity of RNAwas retrotranscribed using a high-capacity complementary
DNA reverse transcription kit (Life Technologies). Real-time polymerase
chain reaction was conducted with SYBR Green (Life Technologies) in a
fast real-time polymerase chain reaction system (Life Technologies). The
real-time polymerase chain reaction assay was performed with 5 ng of
complementary DNA per well, and the thermocycling conditions were
95C for 10 min and 40 cycles of 95C for 15 s followed by 60C for
1 min. Calculations were made from measurement of triplicates of each
sample. The relative amount of messenger RNA (mRNA) was calculated
with the comparative 2-DDCt method. Gene expression was normalized to
36b4. Primer sequences are available on request.
Statistical Analysis. The data shown are the mean 6 SD of 3–5
experiments. Statistical significance was estimated with the Student
t test for unpaired observations or ANOVA followed by the Bonferroni
test when appropriate. Differences with values of P less than 0.05
were considered statistically significant.
Animal Model Studies
Mouse Model. Animal care and experimental procedures were
performed according to directive 2010/63/EU of the European Parlia-
ment, and the studies were approved by the Institutional Committee on
Bioethics (authorization 28079-37A to the Instituto de Investigaciones
Biomédicas).
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PFKFB3 In Vivo Silencing. A mixture of at least 3 different
Silencer Select predesigned silencer RNAs for PFKFB3 was obtained
from different sources (Ambion/InvivoGen, OriGene, or Sigma-Aldrich).
The transfection mixture was prepared using Invivofectamine 2.0
(InvivoGen) and was administered intraperitoneally at 5 mg/kg per
dose, following the instructions of the supplier. Administration of the
corresponding scrambled (negative) RNAs was used to ensure the
specificity of the silencing.
Atherogenesis in ApoE-Deficient Mice and 18F-FDG PET Image
Analysis. Thirty male ApoE-deficient mice 3–4 mo old were fed a
high-fat/high-cholesterol diet for 3 wk, and after anesthesia with iso-
flurane, 18F-FDG (37 MBq/kg; 0.2 mL) was administered intraperito-
neally and the 18F emission was analyzed in a small-animal CT/
SPECT/PET system (Inveon; Siemens). The images were analyzed
and quantified as previously described (9). Briefly, the first axial slice,
representing the descending aorta (the first PET/CT slice clear of the
aortic arch), and 5 consecutive slices at intervals of 3 mm were averaged
to obtain the SUVmax. Measured background SUVs from the paraspinal
muscles were used to obtain a corrected TBR. When PFKFB3 was si-
lenced, the silencer RNAs were administered at days 3, 7, 10, and 12 after
high-fat/high-cholesterol administration. A mixture of scrambled RNAs
was used as control and administered at the same periods. GM-CSF (37.5
mg/kg) was intravenously administered on day 12. The animals were
processed on day 14 for images and biochemical analyses.
Rabbit Model. Nine male New Zealand White rabbits (Charles
River Breeding Laboratories) were included in the study. Seven of the
rabbits were initiated on a 0.3% cholesterol, 4.7% peanut oil hyper-
lipidemic diet for 6 mo to precipitate the development of atheroscle-
rosis. One week after beginning the high-cholesterol diet, the animals
were briefly anesthetized using ketamine and xylazine, and aortoilio-
femoral denudation was performed by balloon catheter injury using a
modified Baumgartner technique (23). Additionally, 2 control rabbits
of similar size and identical origin were maintained on standard rabbit
chow for 6 mo. No catheterization or other invasive procedure was
performed on the control animals.
Rabbit PET/CT Imaging Protocol. After 6 mo of the prescribed
diet, 8 atherosclerotic animals and 2 healthy controls underwent 18F-
FDG PET imaging. The animals were injected with a 37 MBq/kg dose
of 18F-FDG, and PET images were obtained on a microPET P4 (Concorde
MicroSystems) or similar system 3 h after 18F-FDG administration to
allow for maximum tracer uptake. The choice of time interval after
18F-FDG injection was based on our previous work in animals (10).
Images were obtained over 20 min and reconstructed using a filtered
backprojection algorithm. The microPET P4 scanner is an animal PET
tomograph with 32 planes over a 7.8-cm axial extent, 19-cm transaxial
field of view, and 22-cm animal port. Within 6 d of PET imaging,
multidetector CT imaging was performed for anatomic coregistration.
GM-CSF Administration to Rabbits. After baseline imaging, 6
animals (4 atherosclerotic animals and 2 healthy controls) were injected
with 100 mg of sargramostim (yeast-derived recombinant human GM-
CSF; Berlex) daily for a total of 3 d. Four atherosclerotic animals received
saline injections at identical time points. One hour after the final injection
on day 3, a 37 MBq/kg dose of 18F-FDG was administered, and PET
imaging was performed 3 h afterward. The biodistribution methods and
results are provided in the supplemental data, available at http://jnm.
snmjournals.org (Supplemental Fig. 1).
18F-FDG PET Image Analysis in Rabbits. The PET images were
analyzed with masking of treatment allocation and temporal sequence.
First, localization of aortic 18F-FDG uptake was aided by coregistering
the PET images with the multidetector CT images. The temporally
masked baseline and follow-up PET image pairs were registered to
their common multidetector CT images using a workstation that allows
multimodal standard image fusion (REVEAL-MVS; Mirada Solutions)
(24). Thereafter, 18F-FDG uptake could be compared for several stacked
aortic segments over time. Aortic 18F-FDG uptake was quantified by
drawing a circular region of interest around the aorta in the axial view,
in 4-mm increments (yielding a stack of 4-mm-thick aortic slices com-
posing the imaged aorta). For each region of interest, the maximal SUV
was recorded. The SUV is the decay-corrected tissue concentration of 18F-
FDG (in kBq/mL) divided by the injected dose per body weight. Back-
ground 18F-FDG uptake was measured in the paraspinal muscles as an
average of ten 20-mm2 region-of-interest samples. SUVmax was then
background-corrected to derive a target-to-background ratio (TBR) for
each aortic slice.
Histologic Analysis in Rabbits. After final imaging assessments, 3
atherosclerotic animals were sacrificed using an overdose of sodium
pentobarbital. The aortas were excised, placed in 10% buffered
formalin, and decalcified according to the standard protocol. The
aortic samples were sectioned transversely at 5-mm intervals and
stained with rabbit macrophage-specific monoclonal antibody RAM11
(Dako Corp.). RAM11 staining was calculated as a percentage of the
stained area over the total cross-sectional area of the transversely
sectioned aortic wall. Multiple segments from each rabbit abdominal
aorta were obtained and compared against the corresponding PET axial
slices. The averaged RAM11 staining for each 5-mm aortic segment was
also obtained and compared with the mean TBR for the same segments.
The association between anatomic histologic segments and corresponding
PET images was based on distances from the renal arteries measured ex
vivo compared with the coregistered multidetector CT images. Control
animals were not sacrificed for histologic analysis because previous
work has demonstrated that there is no inflammation (percentage rabbit
antimacrophage antibodies [%RAM11 staining]) within the aortic wall of
control rabbits (24).
Statistical Analysis. Data were analyzed using SPSS, version 22
(IBM). Continuous parameters are reported as mean 6 SEM. Statis-
tical analysis comparing the change in the TBR across atherosclerotic
segments (before and after treatment with GM-CSF or saline) was
performed using the Wilcoxon signed-rank test. The Spearman method
was used to assess the correlation between atherosclerotic tissue uptake of
18F-FDG after GM-CSF (measured by PET, as TBR) and the subsequent
histopathologic assessment of inflammation in those same sections
(%RAM11 staining). A P value of less than 0.05 was considered statis-
tically significant.
RESULTS
GM-CSF Augments Glycolytic Flux via Upregulation
of PFKFB3
In human macrophages, incubation with GM-CSF resulted
in rapid phosphorylation of STAT5 in Y694 (Fig. 1A) and meta-
bolic reprograming of macrophages (including modest increases
in hexokinase-1 and hexokinase-2; Fig. 1B). Moreover, there was a
substantial increase in PFKFB3, which was negligibly expressed be-
fore GM-CSF (Figs. 1B and 1C). The PFKFB3 isoform has a much
higher net kinase activity than the constitutively expressed PFKFB1
isoenzyme. Thus, upregulation of PFKFB3 would be expected to pro-
duce substantially higher glycolytic flux. The specificity of this asso-
ciation was demonstrated using silencing RNA for PFKFB3, which
resulted in attenuated induction of PFKFB3 (Fig. 1D), but not by
the scrambled RNA sequence. Additionally, the selective PFKFB3
inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) did not
alter the induction of this gene by GM-CSF (Fig. 1D).
In line with the increased expression of glycolytic enzymes,
GM-CSF resulted in a substantial increase in glycolytic flux
(measured as Fru-2-6-P2 concentration, a potent activator of gly-
colysis; Fig. 2A). This augmented glycolytic flux was attenuated
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after inhibition of PFKFB3 by 3PO. In concert with the rise in Fru-
2-6-P2 concentration, GM-CSF also increased lactate accumula-
tion in the medium (Fig. 2B).
Additionally, GM-CSF resulted in a selective (not achieved by
heat-denatured GM-CSF) and modest increase in proinflammatory
activation of the macrophages (as evidenced by macrophage TNF-a
production; Fig. 2C). Furthermore, antagonism of TNF-a (using a
neutralizing anti-TNF-a antibody) attenuated the glycolytic flux
(measured as Fru-2-6-P2 concentration) after GM-CSF (Fig. 2D).
GM-CSF Augments Deoxyglucose Accumulation Within
Cultured Macrophages
Incubation of macrophages with GM-CSF upregulated the incor-
poration of [U-14C]-2-deoxyglucose in a manner that paralleled its
impact on glycolytic flux (Figs. 2E and 2F). A time-dependent in-
crease in 2-deoxyglucose uptake was observed after GM-CSF chal-
lenge (Fig. 2E). The rate of 2-deoxyglucose uptake was significantly
greater than in control cells, was increased as early as 2–4 h after
GM-CSF exposure, and persisted, at a more pronounced rate of in-
crease, at later time points (P , 0.01). Also, in parallel with the
impact of GM-CSF on glycolysis, blocking of TNF-a or inhibition
(3PO) or silencing (siPFKFB3) of PFKFB3 resulted in reduced
2-deoxyglucose uptake (Figs. 2E and 2F).
GM-CSF Increases Atherosclerotic 18F-FDG Uptake In Vivo
Without Altering Lesion Area
The in vivo impact of GM-CSF on chronic atherosclerotic
inflammation was investigated in 2 animal models (mouse and
rabbit). In Apoe2/2 mice fed for 2 wk on a high-fat diet,
administration of GM-CSF (on day 12 of
the diet) significantly enhanced the aortic
18F-FDG uptake (TBR measured at 48 h
after administration was increased by
70% relative to animals treated with vehi-
cle; P , 0.01), whereas aortic 18F-FDG
uptake did not increase in animals given
both GM-CSF and silencer mRNA for
PFKFB3 (Fig. 3A). When the lesion area
was evaluated after oil red staining, the
single-dose administration of GM-CSF did
not influence the lipid accumulation (Fig.
3B). Moreover, the increased TBR was
the result of a significant increase in target
(arterial) activity, whereas the background
activity did not significantly change with
GM-CSF (Fig. 3C).
Further, to assess the impact of GM-CSF
on potential infiltration of circulating mono-
cytes into the aortic wall, the whole aorta
from treated animals was analyzed using
real-time quantitative polymerase chain re-
action. As Figure 3D shows, the macrophage-
specific gene, Lxra, did not increase after
GM-CSF administration when compared
with specific endothelial and smooth muscle
cell markers (i.e., F8, Sm22a, Myh11, and
Col1a1). Together, these results suggest a
minimal contribution of GM-CSF, if any,
to enhance the recruitment of monocytes to
the lesion area, in agreement with previous
data (9).
In atherosclerotic rabbits, GM-CSF administration was associated
with an approximately 73% increase in 18F-FDG uptake (5.876 0.14
vs. 10.096 0.40 before vs. after GM-CSF, arterial TBR6 SEM, P,
0.01; Figs. 4A and 4B). Atherosclerotic animals injected with saline
showed no statistically significant change in TBR (4.17 6 0.32 vs.
4.08 6 0.20, P , 0.01) over the same time period. Further, in
healthy rabbits without atherosclerotic inflammation, GM-CSF
administration was associated with a decrease in the arterial signal
(2.26 6 0.07 vs. 1.47 6 0.17, P , 0.01). In contrast, blood 18F-
FDG activity did not differ between rabbits given GMCSF and
those given saline (supplemental data). Collectively, these data
demonstrate that administration of GM-CSF augments 18F-FDG
uptake within the arterial wall in atherosclerotic but not in normal
rabbits.
Atherosclerotic 18F-FDG Uptake After GM-CSF Correlates
with Macrophage Density
Next, we tested the hypothesis that arterial 18F-FDG uptake
after GM-CSF correlates with histologic macrophage density. To
do so, we compared 18F-FDG uptake in atherosclerotic rabbits
with macrophage-specific %RAM11 staining in histologic
segments of aortas from sacrificed animals. We observed that
18F-FDG uptake significantly correlated with %RAM11 staining
(R 5 0.76, P 5 0.002; Fig. 5).
DISCUSSION
Here, we have shown that GM-CSF augments the glycolytic
flux in vitro (via a mechanism that depends on PFKFB3) and
FIGURE 1. GM-CSF augments 2-deoxyglucose uptake and glycolytic flux in human macro-
phages via PFKFB3. (A and B) Human monocytes were differentiated to macrophages. Cells
were exposed to human GM-CSF (10 ng/mL) for the specified time duration, and phosphorylation
of STAT5 in Y694 (A) and levels of glycolytic enzymes (B) were determined. Addition of GM-CSF
induced significant expression of hexokinase-1, hexokinase-2, and mainly PFKFB3. (C) Cells
exposed to native GM-CSF demonstrated increased PFKFB3 expression compared with incu-
bation with heat-inactivated GM-CSF (10 min at 80°C). (D) GM-CSF–mediated increase in
PFKFB3 expression (right) was decreased with addition of silencer to PFKFB3 but not by selec-
tive PFKFB3 inhibiter 3PO, demonstrating specificity of silencer. Cells were treated with mixture
of siPFKFB3 for silencing PFKFB3 18 h before challenge with GM-CSF. Results show mean ± SD.
*P , 0.05 vs. same condition in control (absence of GM-CSF or 0 h). **P , 0.01 vs. same
condition in control (absence of GM-CSF or 0 h). ##P , 0.01 for scRNA vs. siPFKFB3 with or
without 3PO. a.u. 5 arbitrary units; GAPDH 5 glyceraldehyde 3-phosphate dehydrogenase; HK 5
hexokinase; scRNA 5 scrambled RNA.
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acutely increases 18F-FDG uptake within inflamed tissues in vivo
(in 2 animal atherosclerotic models). These data suggest that GM-
CSF, when administered as an adjunctive imaging agent, improves
the sensitivity for detecting inflammatory foci. Further investiga-
tions to evaluate the clinical impact of GM-CSF in 18F-FDG PET
imaging are warranted.
GM-CSF is an endogenously circulating cytokine that is present
at basal levels in serum. Recombinant human GM-CSF, a widely
available and clinically used immunomodulatory agent, was first
approved by the Food and Drug Administration in 1991 for the
acceleration of myeloid recovery after autologous bone marrow
transplantation. Since that time, the use of GM-CSF has expanded.
GM-CSF acts to mobilize peripheral-blood progenitor cells,
resulting in shorter durations of neutropenia in patients re-
ceiving induction chemotherapy for hematologic malignancies
(25). Further, it is widely appreciated that GM-CSF increases
the hematopoietic 18F-FDG signal and that the heightened signal
may persist for weeks after the last dose
(16,26–31). The findings of this study pro-
vide further understanding of the mecha-
nisms underlying this observation.
Here, we show that GM-CSF acutely
increases the expression of PFKFB3, result-
ing in increased glycolytic flux compared
with the constitutively expressed PFKFB1,
since PFKFB3 has a much higher net kinase
activity, therefore increasing the intracellular
levels of Fru-2,6-P2 and accelerating the up-
per part of glycolysis. Further, we found that
the upregulation of PFKFB3 was necessary
for the increased glycolytic flux seen with
GM-CSF in both in vitro (human macro-
phages) and in vivo models (mice): blocking
PFKFB3 (with silencer RNA specific for
PFKB3 or inhibiting its activity using 3PO)
resulted in levels of glycolysis that were only
slightly above baseline levels. Additionally,
we observed that antagonism of TNF-a (us-
ing an antibody against TNF-a) resulted in
an attenuation of glycolytic flux after GM-
CSF. This finding is consistent with the prior
observation that PFKFB3 activation results in
augmented TNF-a production and that the
TNF-a in turn leads to increased PFKB3
(via a mechanism that relies on HIF-1a (9).
Moreover, we found that GM-CSF pro-
vided a roughly 3-fold increase in glycolytic
flux and a similar increase in macrophage
2-deoxyglucose uptake in vitro. Similarly,
in the Apoe2/2 mice and in the rabbit
models of atherosclerosis, we observed
an approximately 70%–73% increase in
18F-FDG uptake. Such increased 18F-FDG
uptake might provide improved detection
of infectious foci.
The studies examining the effects of
chronic GM-CSF administration on ath-
erosclerosis have provided inconsistent
findings (32). In one study, hyperlipidemic
LDLR2/2 mice with a GM-CSF defi-
ciency exhibited a 20%–50% decrease in
aortic lesion size, depending on the location of the lesions and the
sex of the animals. In another, Apoe2/2 mice treated with GM-
CSF chronically manifested an increased atherosclerotic-lesion
area. However, in another study, Apoe2/2 mice with a genetic
deletion of GM-CSF demonstrated an increased atherosclerotic-lesion
size (without changes in plasma cholesterol). It follows then, that both
proatherogenic and antiatherogenic properties have been attributed to
GM-CSF. Accordingly, the consequences of long-term GM-CSF ad-
ministration have yet to be determined. However, clinical experience
with short-term GM-CSF administration suggests no increased
risk of cardiovascular complications (33).
Clinical Implications
The concept of transiently “stimulating” macrophages with GM-
CSF to improve the signal-to-noise ratio of inflammatory foci is
analogous to the use of exercise stress testing to enhance the detection
of myocardial ischemia. With electrocardiographic exercise treadmill
FIGURE 2. PFKFB3 mediates increase in 2-deoxyglucose uptake in human macrophages treated
with GM-CSF. (A) Intracellular levels of Fru-2,6-P2 were determined at the indicated times with
and without GM-CSF and in absence or presence of PFKFB3 inhibitor 3PO (5 μM). GM-CSF
augments Fru-2,6-P2 levels, which are attenuated in presence of 3PO, demonstrating critical role
of expression of PFKFB3 after GM-CSF treatment. (B) Lactate accumulation in culture medium
was determined at 18 h with and without native or heat-inactivated GM-CSF and in absence or
presence of 3PO (5 μM). Lactate levels (by-product of glycolysis) increase with GM-CSF expo-
sure and are dampened by 3PO. (C) TNF-α levels were determined in culture medium after
challenge with native or heat-inactivated GM-CSF. (D) Intracellular levels of Fru-2,6-P2 were
determined at the indicated times with GM-CSF and in presence of neutralizing anti-TNF-α
antibody. GM-CSF augments Fru-2,6-P2 levels, which are attenuated in presence of neutralizing
anti-TNF-α antibody. (E) 2-deoxyglucose uptake was determined at the indicated times with and
without GM-CSF and in absence or presence of neutralizing anti-TNF-α antibody (20 ng/mL) or
PFKFB3 inhibitor 3PO (5 μM). 2-deoxyglucose significantly increases with addition of GM-CSF.
This effect was diminished with neutralizing anti-TNF-α antibody and with 3PO. (F) To analyze
contribution of PFKFB3 to enhancement of glycolytic flux elicited by GM-CSF, macrophages
were transfected for 18 h with specific siRNA to silence PFKFB3 or with corresponding inactive
RNA control (scRNA) and in absence or presence of 3PO, followed by activation for 18 h with GM-
CSF. 2-deoxyglucose uptake was significantly decreased after silencing PFKFB3 compared with
corresponding control (scRNA) or inhibition with 3PO. Data are mean ± SD. *P , 0.05 vs. same
condition in control (absence of GM-CSF or 0 h). **P , 0.01 vs. same condition in control
(absence of GM-CSF or 0 h). #P , 0.05 for GM-CSF vs. heated GM-CSF, with 3PO plus GM-
CSF. ##P , 0.01 for GM-CSF vs. heated GM-CSF, with 3PO plus GM-CSF. IgG vs. anti-TNF-α
antibody or scRNA vs. siPFKFB3 with or without 3PO. scRNA 5 scrambled RNA; siRNA 5
silencer RNA.
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testing, the detection of occlusive coronary lesions (those that cause
myocardial ischemia) is limited under resting conditions. However,
when exercise is used to temporarily induce myocardial ischemia
(leading to diagnostic changes on the electrocardiogram), a substan-
tial boost in test sensitivity is yielded. At the same time, the induction
of transient ischemia during exercise has been shown to be remark-
ably safe. Analogously, we propose further examination of the use of
GM-CSF to transiently and safely provoke an inflammatory signal.
This transient provocation may substantially improve the detection of
inflammatory lesions, such as atherosclerotic or infectious foci.
Importantly, GM-CSF has a relatively safe track record, even
when used for extended periods. The in vivo data presented within
this study and from others provide some explanation of why GM-
CSF has a relatively modest proinflammatory profile compared
with some other cytokines. We previously reported that lipopoly-
saccharide induces a 50- and 15-fold greater increase in TNF-a
mRNA and protein production, respectively, compared with GM-
CSF (9). In that experiment as well, GM-CSF resulted in a 6-fold
increase in Arg-1 mRNA, a prototypical marker of M2 polariza-
tion. In fact, the increase in Arg-1 mRNA exceeded the increase in
TNF-a mRNA, supporting the notion that GM-CSF provides a
balanced increase in M1 as well as M2 polarization, yielding an
intermediate polarization profile.
Moreover, the safety of GM-CSF has already been established
in patients who have a preponderance of atherosclerotic risk factors,
as well as in critically ill patients (33). In fact, GM-CSF may have
benefits in chronic atherosclerosis (potentially related to augmen-
tation of progenitor cell release) and is being examined as a therapy
for chronic peripheral arterial disease (ClinicalTrials.gov identifier
NCT01408901) (34,35).
18F-FDG PET imaging has already become a critical tool in the
localization of infections in the setting of fever of unknown origin
(36,37). Our findings offer justification to further explore the use
of GM-CSF as an adjunctive agent for 18F-FDG PET imaging of
inflammation, in both acute and chronic inflammatory diseases
(such as atherosclerosis and infections). In such cases, GM-CSF
would be expected to transiently increase the 18F-FDG signal
within inflammatory cells and thus enhance the sensitivity, and
possibly the specificity, of PET/CT imaging for detecting an in-
flammatory lesion.
Use of GM-CSF as an Adjunctive Imaging Agent in
Other Settings
GM-CSF might also aid in the characterization of malignancies.
18F-FDG PET/CT imaging has proven to be an invaluable tool in
the workup of oncologic processes (38). The biologic basis of 18F-
FDG accumulation in malignant tumors results in part from the
relatively high glycolytic rates found within malignant cells. How-
ever, tumor-associated macrophages also constitute an important
fraction of oncologic tissues and provide an additional locus of
intratumor 18F-FDG accumulation (10). Occasionally, one cannot
FIGURE 3. In vivo augmentation of 18F-FDG uptake after GM-CSF
administration in mice. (A) 18F-FDG uptake in atherosclerotic mice (n 5
30). Animals received siPFKFB3 (n 5 10) or scRNA (n 5 8) at days 3, 7,
10, and 12 after high-fat/high-cholesterol administration. GM-CSF (37.5
μg/kg; n 5 15) or saline (n 5 15) was intravenously administered on day
12, and 18F-FDG and PET analysis was performed on day 14. (B) Aortas
were stained with oil red and images evaluated with Image J. (C) Aver-
age target and background SUVs from A were compared (n 5 15 ani-
mals for each group). Target SUVs were higher with than without
GMCSF (3.38 ± 0.46 vs. 2.70 ± 0.26; P 5 0.046). Background SUVs
were unchanged with vs. without GMCSF (0.54 ± 0.10 vs. 0.55 ± 0.10;
P 5 0.53). (D) In parallel experiment, aortas from untreated (n 5 4) or
GM-CSF–treated animals (n 5 4) as described in A were isolated and
RNA extracted for analysis of the indicated genes representative of
endothelial cells (F8), smooth muscle cells (Sm22a, Myh11, Col1a1),
and macrophages (Lxra). Data are mean ± SD. *P , 0.05 vs. same
condition in absence of GM-CSF. ##P , 0.01 vs. same condition with
scRNA. a.u. 5 arbitrary units; scRNA 5 scrambled RNA.
FIGURE 4. In vivo augmentation of 18F-FDG uptake after GM-CSF
administration in rabbits. (A) 18F-FDG uptake in rabbits (n 5 9) before
and after challenge with cytokine GM-CSF or saline shows significant
increase in 18F-FDG uptake in atherosclerotic rabbits (P , 0.001). 18F-
FDG uptake is expressed as TBR compared with baseline imaging.
(B) Representative image of 18F-FDG signal enhancement demonstrat-
ing increased 18F-FDG uptake in descending aorta before and after
GM-CSF.
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differentiate whether the 18F-
FDG signal originates within
tumor or immune cells (espe-
cially after some chemothera-
peutic regimens, which can
activate immune cells while
decreasing tumor activity). In
these cases, the use of GM-
CSF may improve diagnostic
accuracy; an increase in lesional
18F-FDG uptake on serial
18F-FDG PET/CT imaging (re-
peated after GM-CSF) may
suggest that the activity was
localized to immune cells.
Furthermore, GM-CSF may
prove useful as an adjunctive
agent for other approaches tar-
geting inflammation. GM-CSF
might enhance macrophage ac-
tivation sufficiently to increase
uptake of other tracers target-
ing inflammation, such as gal-
lium DOTATATE PET and
superparamagnetic iron oxide
nanoparticles. This is particularly facilitated by the fact that GM-CSF
activates macrophages via mechanisms that promote both M2
(phagocytic) and mild M1 actions. With M2 activation comes an
increase in uptake of nanoparticles such as superparamagnetic iron
oxide (39). GM-CSF–enhanced imaging of superparamagnetic iron
oxide and other nanoparticles should be further explored.
Limitations
This study is not without limitations. The optimal duration and
dosing of GM-CSF was not examined in this study (only a 3-d
GM-CSF regimen was examined). Thus, it is not clear from these
data whether a single injection of GM-CSF would suffice to
provide the desired boost in 18F-FDG uptake. A multiday regimen
would come at increased complexity, cost, and potential risks.
Further, since only one imaging interval was studied, the optimal
time point for 18F-FDG PET/CT imaging after GM-CSF adminis-
tration has not been determined. Future human studies are needed
to assess the impact of a simplified GM-CSF regimen on 18F-FDG
PET/CT imaging.
CONCLUSION
GM-CSF augments macrophage glycolytic flux in vitro via a
mechanism dependent on PFKFB3 and increases 18F-FDG uptake
in vivo in animal atherosclerotic models. GM-CSF is an approved
and clinically used medication with an established safety profile.
Future larger studies should explore the potential of using GM-
CSF as an adjunctive imaging tool to improve detection of in-
flammation.
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Supplemental Figure 1: Biodistribution Data. Biodistribution studies were done in a subset of 4 animals 
that had undergone PET/CT imaging (2 that had received GM-CSF and 2 after saline). Animals were killed 
with an overdose of pentobarbital sodium. To assess biodistribution, samples of blood, heart, lung, liver, 
spleen, kidney, adrenal gland, stomach, small intestine, skeletal muscle, and bone marrow were collected and 
weighed. A well-type gamma counter was used to measure radioactivity (LKB model 1282; LKB 
Instruments). Measurements were recorded as counts per minute less background and were corrected for 
radioactive decay. Results were expressed as percentage injected dose per gram (%ID/g). 
 2 
 
Supplemental Figure 2: Blood Time–Activity Curves. Blood time–activity studies were done in a subset of 
4 animals (2 that had received GM-CSF and 2 after saline). After administration of 18F-FDG (mCi), venous 
blood samples were taken at 16 time points. A well-type gamma counter was used to measure radioactivity 
(LKB model 1282; LKB Instruments). Measurements were recorded as counts per minute less background 
and were corrected for radioactive decay. Results were expressed as percentage injected dose per gram 
(%ID/g). There was no difference between the activity curves after GM-CSF vs. saline. 
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Abstract
Macrophages are present in a large variety of locations, playing distinct functions that are determined by its
developmental origin and by the nature of the activators of the microenvironment. Macrophage activation
can be classiﬁed as pro-inﬂammatory (M1 polarization) or anti-inﬂammatory-pro-resolution-deactivation
(M2), these proﬁles coexisting in the course of the immune response and playing a relevant functional role
in the onset of inﬂammation (Figure 1). Several groups have analysed the metabolic aspects associated with
macrophage activation to answer the question about what changes in the regulation of energy metabolism
and biosynthesis of anabolic precursors accompany the different types of polarization and to what extent
they are necessary for the expression of the activation phenotypes. The interest of these studies is to
regulate macrophage function by altering their metabolic activity in a ‘therapeutic way’.
Macrophages: a heterogeneous population
Macrophages constitute a diverse population of cells that
has been clarified in recent years; tissue macrophages have
their own self-renewal mechanisms, starting from committed
resident cells, whose origin appears to be related to early steps
in the development from precursors of the yolk sac [1]. These
highly specialized subsets receive distinct denominations as a
function of their discovery and are present in adult organisms
[2]. Examples of these are the microglia in the central nervous
system, Kupffer cells in the liver and Langerhans cells in
the skin [2]. These cells exhibit low rates of self-renewal,
and express specific surface markers and anti-apoptotic genes
of the B-cell lymphoma 2 (Bcl2)-Bcl-xL family that ensure
their long-lasting function [3]. In addition to this, circulating
monocytes are recruited at the sites of inflammation and
contribute to mount the innate immune response [2,4–6].
These infiltrating cells, upon activation, are maintained alive
for 2–3 days, being removed by apoptosis [6].
Energy fuelling of macrophages
Macrophages are essentially glycolytic cells, regardless of
the combination of phenotypic challenges; pro-inflammatory
Key words: glycolysis, inﬂammation, inhibitors, isoenzyme, macrophage, metabolism.
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macrophages increased glucose metabolism in the absence
of proliferation, whereas anti-inflammatory/pro-resolution
macrophages retain the same dependence on glycolysis but
exhibiting modest glucose consumption, like in resting or
resident counterparts [7]. This high glycolytic capacity was
recognized by Otto Warburg as a characteristic feature of
cancer and immune cells, such as macrophages. It is the mi-
micry (or real) of hypoxic conditioning of macrophages the
main driving force conveying to the expression of most of the
genes associated to the glycolytic phenotype [7,8]. Therefore,
targeting glycolysis has become an important objective in sev-
eral anti-inflammatory therapeutic strategies inwhichmacro-
phages are involved, fromatherogenesis to cancer, fibrosis and
different immune diseases. There are evidence-based reasons
for such developments: high glycolytic flux contributes to
biosynthetic pathways providing precursors for de novo
ribonucleotide synthesis, amino acid replenishment for new
protein synthesis and fatty acids biosynthesis. All these
processes canbe attenuated interfering glucosemetabolism, as
recently described for the development of atherogenesis [4,9].
The other main source of energy for most cells is the
Krebs cycle/oxidative phosphorylation [tricarboxylic acid
(TCA)/OXPHOS] pathway. One characteristics of pro-
inflammatory polarization is the expression of nitric oxide
(NO) synthase (NOS2) [10,11]. Under these conditions,
NO acts as a potent inhibitor of cytochrome c oxidase in
the OXPHOS pathway, avoiding mitochondrial respiration
and ATP generation. However, in human macrophages,
the inducibility of NOS2 is negligible and NO is not
produced, preserving the activity of the OXPHOS [11].
Nevertheless, when O2 consumption is analysed in M1
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Figure 1 Schematic representation of macrophage stimulation and polarization
The different phenotypes are induced after challenges with the indicated stimuli, resulting in the expression of the indicated
mediators (italic). Abbreviations: CC, chemokine; CK, cytokine; GR, glucocorticoid receptor; IFNγ , interferon γ ; LTA, lipoteichoic
acid; LXR, liver X receptor; MMP, matrix metalloproteinase; NLR, nt-binding domain and leucine-rich repeat; NOD, nt-binding
oligomerization domain receptor; PG, prostaglandin; PGN, peptidoglycan; PPAR, peroxisome proliferator-activated receptor;
RNI, reactive nitrogen intermediate; ROS, reactive oxygen species; TGF, transforming growth factor.
human macrophages the use of oxidative TCA/OXPHOS
pathway is still impaired. The mechanisms interfering with
this oxidative capacity remain elusive, but the inhibition of
the pyruvate flux to the mitochondria and the accumulation
of TCA and other intermediates altering the normal flux of
electrons and substrates in the mitochondria may be under
themechanisms of this impairedmetabolic issue. An ancillary
consequence of this process is the loss of viability of M1
macrophageswhen glucose supply is reduced, as evidencedby
the lack of recovery aftermitochondrial depolarization [9].
Glucose fate regulation in macrophages
Regulation of glycolysis is very dependent on the cell
type and on the energy demands in its environment.
One way to accomplish this is through the expression of
specific isoenzymes, adapting optimal kinetic and regulatory
properties with the needs for cell function. This is in
addition to covalent modifications in glycolytic enzymes
and recent proteomic analysis shows a huge variety of post-
translational stoichiometries that are explained on the basis
of coexistence of spatially distributed, distinctly modified
enzymes contributing to a fine tuning of its catalytic activity
and opening an additional degree of complexity. This is true
for macrophages confronted to specific stimuli, ranging from
the presence of pathogens to death cells, all occurring under
conditions of restricted availability of energetic substrates,
such as glucose, amino acids and oxygen.
An additional emerging issue is the differential processing
of the mRNA of glycolytic enzymes in macrophages,
yielding isoforms with altered N-terminal domains due to
alternative splicing. These differences involve the use of
different promoters, which vary among mammalian species,
the presence of non-coding RNA sequences, the occurrence
of selective splicing etc. Perhaps the most paradigmatic
situation is that of pyruvate kinase (PK) muscle-type 2
(PKM2) that, depending on its compartmentalization is
involved in the metabolic activity, but also in transcriptional
regulation, stabilization of hypoxia-inducible factor (HIF)-
1α and secretion of high-mobility group box 1 (HMGB1)
and interleukin (IL)-1β. Indeed, inhibition of PKM2 activity
with shikonin protects mice form lethal septic shock
through an impairment of the lower part of the glycolytic
pathway [12,13]. These results stress the relevance of
glycolysis to maintain the full pro-inflammatory phenotype
in macrophages [14–17].
Glycolytic targeting of macrophages
Rewiring of glucose metabolism can be achieved by altering
substrate availability, through directly targeting enzymes
with selective inhibitors or by creating a metabolic imbalance
among the different fluxes that use glucose (Figure 2).
Altering substrate availability is a difficult issue, but diet-
dependent conditioning of macrophage metabolism is an
open issue; e.g., ketogenic diets or poly-unsaturated fatty
acids that generate pro-resolution metabolites interfering
with the basic programmes of macrophage polarization
[18,19].
Several selective inhibitors of glycolytic enzymes have
been developed in recent years. Since M1 macrophages
have an enhanced glucose uptake due to overexpression of
glucose transporter 1 (GLUT-1) the use of glucose analogues
may serve to transiently attenuate glucose metabolism. This
approach, because it affects to the upper part of glycolysis,
not only prevents energy supply in the macrophage but
also the use of glucose-6-phosphate by the oxidative
pentose phosphate pathway arm that is critical to support
NADPH replenishment and also for ribose synthesis [9,20].
Interestingly, the lower part of glycolysis, namely the balance
between the lactate export/import is clearly imbalanced
towards the export via the monocarboxylic acid transmem-
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Figure 2 Changes in glycolytic enzymes in macrophages in the
course of activation
The main regulatory enzymes are shown in black (resting and
anti-inﬂammatory phenotype) and red (pro-inﬂammatory phenotype.
Post-traslational changes (phosphorylation) and alternative splicing
isoenzymes are depicted as P and S respectively. The activators and
inhibitors are described with the + or − signs. Abbreviations: ALD,
aldolase; PPP, pentose phosphate pathway.
brane transporter MCT4 (monocarboxylate transporter 4;
encoded by the slc16a3 gene) that is highly expressed in
M1 macrophages. The use of inhibitors for this transporter
in oncology is under clinical trials. However, the protein
encoding the import of lactate (MCT1) isminimally expressed
in the macrophage membrane [21,22]. Indeed, it is to note
that due to the high activity of lactate dehydrogenase (LDH)
in the macrophage and because this enzyme maintains the
intracellular balance between pyruvate and lactate, but also
betweenNADH andNAD, all at concentrations in the range
of the chemical equilibrium of the reaction, the export of
lactate needs to be well-regulated to avoid NADH depletion.
Resting and M2-challenged macrophages express hexok-
inase (HK)-1 as the main activity phosphorylating glucose.
However, in M1 macrophages HK-2 is highly expressed.
This isoform is mainly present in the particulate fraction
of macrophage extracts, associated to the mitochondrial
adenine nt translocator (ANT)–permeability transition pore
complex [23]. In cells exhibiting aerobic metabolism, this
association of HK-2 to the ANT is thought to enhance
the efficient use of the ATP generated by the mitochondria;
however, this is not the case of macrophages that exhibit a
modest OXPHOS activity and the biological significance of
this accumulation of HK-2 in the mitochondrial fraction is
unclear. In ex vivo experiments, the use of glucose isomers
lacking the hydroxy group at the C-2 position retain the
phosphorylation in the C-6 position but are unable to be
converted into further glycolytic products at the time that
accumulate and potently inhibit HK-1 and HK-2 activities.
Indeed, 2-fluoro- or 2-deoxy-glucose or mannose derivatives
have been used for the quantification of the rate of glucose
uptake and phosphorylation of highly glycolytic cells and,
upon accumulation, can deplete the intracellular ATP levels
leading to cell death [9,24]. Although the Ki values of the
different 2-deoxy-glucose isomers (including mannose) for
HK has been a matter of debate, analysis of the kinetic
properties using purified enzyme shows minimal differences
among them [25]. However, the possibility of the use of
these C-6 phosphoesters by phosphatases or other enzymes
cleaving the phosphate group may lay on the basis of the
different properties of these molecules as in vivo diagnosis
tracers for the glycolytic capacity of the macrophages at
different locations [24].
One relevant target to modulate glycolysis in mac-
rophages are the 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase isoenzymes (PFKFB1-4) [26]. These isoen-
zymes maintain a tight control on the futile cycle involved
in the synthesis and degradation of Fru-2,6-P2, a potent
activator of phosphofructokinase (PFK), the enzyme that
catalyses the phosphorylation of Fru-6-P to Fru-1,6-P2
and constitutes the second ‘irreversible’ step of glycolysis
[27]. The main PFK activity present in macrophages is
a combination of the liver (PFKL) and platelet (PFKP)
isoenzymes, with a minimal representation of the skeletal
muscle isoform (PFKM) and integrated into different hetero-
or homo-tetrameric complexes. This enzyme is submitted to
control by acidic pH that, in turn, enhances the sensitivity
to the inhibition by several effectors, among them ATP
as the main contributor to inhibit the flux through this
step.However, Fru-2,6-P2 provokes a conformational change
that releases the inhibition caused by pH and ATP [27].
Therefore, tight control of Fru-2,6-P2 levels appears to be a
key regulator of the upper glycolytic flux. Regarding PFKFB
isoenzymes, these are bifunctional enzymes consisting in
the fusion of two separated domains, one containing the
kinase activity and another independent domain carrying the
bisphosphatase activity [26]. The balance between the kinase
and bisphosphatase activities varies among the isoenzymes
and can be regulated by covalent modification by several
protein kinases [26,28,29]. Resting and tissue macrophages
mainly express the liver type or PFKFB1 isoform, char-
acterized by a dominant bisphosphatase compared with
kinase activity, thus maintaining low levels of the effector
Fru-2,6-P2 [7]. However, M1 macrophages exhibit a rapid
fall in the mRNA levels of PFKFB1 together with a
progressive decline in its protein levels, accompanied by
C©2015 Authors; published by Portland Press Limited
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a rise in the expression of the PFKFB3 isoform. This
isoformhas a dominant kinase comparedwith bisphosphatase
activity resulting in a rise in the concentration of Fru-
2,6-P2 and full activation of upper glycolysis. In addition
to this, PFKFB3 activity is also modulated in a positive
way through phosphorylation by AMP-dependent protein
kinase (AMPK), protein kinase A (PKA) and protein kinase
C (PKC), all at Ser461 [26]. This shift in the PFKFB
isoforms offers the advantage of the use of selective PFKFB3
inhibitors to interfere glycolysis. One of such inhibitors is
the dipyridinyl propenone 3-(3-pyridinyl)-1-(4-pyridinyl)-
2-propen-1-one (3PO), a molecule developed under a
structure/activity computational analysis approach [9,30].
Indeed, recent advances on the knowledge of functions of
PFKFB3 have revealed an important contribution for this
isoenzyme in favouring angiogenesis by endothelial cells and
proliferation of tumour cells [28,31–36]. In M1 macrophages
silencing PFKFB3 with selective siRNAs or inhibition of
its activity with 3PO has profound effects on cell viability
and on the progress of atherogenesis in apolipoprotein E-
deficient substitute (ApoE)-deficient mice fed a high-fat and
cholesterol-rich diet [9].
In lower glycolysis, a key regulatory activity is PK.
Recent data suggest a precedent unrecognized role for PK
in macrophage glycolysis. PK catalyses the last major step in
glycolysis transforming phosphor-enol-pyruvate (PEP) into
pyruvate together with the generation of one ATP molecule
from ADP. Macrophages express high levels of the PKM.
From this locus two isoforms can be generated: PKM1 and
PKM2. Both forms coexist in resting macrophages and are
down-regulated in a time-dependent way upon activation
with toll-like receptor (TLR) ligands (M1 cells). Under these
conditions, the formation of different complexes PKM1–
PKM2 is expected, but the PKM2 isoform is dominant in
M1 macrophages. PKM2 retains the ability to be activated
by Fru-1,6-P2, integrating the co-ordination between the
upper with the lower part of glycolysis [37–40]. In addition
to this, PKM2 shows complex organization behaviour; the
enzyme exists in equilibrium between dimeric and tetrameric
forms [12,13,41,42]. PKM2 dimers exhibit a lesser affinity
for PEP but can stabilize HIF-1α and activate HIF-1α-
dependent transcription, among others, the expression of
PFKFB3 and the HMGB1 proteins [13,35]. In addition to
this, PKM2 dimers can bind directly to histone H3 and
transfer the phosphate from PEP to histone H3 at Thr11
allowing the dissociation from cyclin D1 (CCND1) resulting
in chromatin remodelling and epigenetic changes [37,39]. To
modulate the balance between the metabolic and genomic
actions of PKM2, several activators and inhibitors have
been developed: N, N′-diarylsulfonamide NCGC00185916
(DASA-58) and thieno-[3,2-b]pyrrole [3,2-d]pyridazinone
NCGC00186528 (TEPP-46) are activators that promote its
metabolic activity, including an enhanced serine biosynthesis;
whereas inhibition with shikonin reduces lactate release by
macrophages and impairs the establishment of a full M1
polarization phenotype [12,13,37,38,41,43]. This modulation
of PKM2 activity can be translated into functional responses;
activation of PK inhibited lipopolysaccharide (LPS)- and
Salmonella typhimurium-induced glycolytic reprogramming,
succinate production andHIF-1α stabilization and inhibition
with shikonin reduced serum lactate and HMGB1 levels and
protected mice from lethal endotoxemia and sepsis [12,13].
Indeed, the presence of the two PKM isoforms establishes a
competition for PEP as substrate and, in so doing, the fall in
PEP levels results in an enhancement of the non-metabolic
PKM2 functions, due to its lower affinity for the substrate.
Concluding remarks
Our data [7,9,44] and those from other groups support the
view that regardless of the challenges used and the availability
of alternative energy substrates, macrophage metabolism is
by more than 90% glycolytic, with limited use of other
fuels for energy purposes; however, the pathways to generate
metabolites by the Krebs cycle and by glutaminolysis are
fully functional and used in part for other purposes [7,45]. In
this context, we have investigated the role of macrophages in
the development of atherogenesis. These studies allowed us
to develop new strategies to evaluatemacrophagemetabolism
in atheromatous lesions and to stabilize them using specific
metabolic-based signatures [9].
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Aims Inflammation is a significant contributor to cardiovascular disease and its complications; however, whether the myocar-
dial inflammatory response is harmonized after cardiac injury remains to be determined. Some receptors of the innate
immune system, including the nucleotide-binding oligomerization domain-like receptors (NLRs), play key roles in the
host response after cardiac damage. Nucleotide-binding oligomerization domain containing 1 (NOD1), a member of
theNLR family, is expressed in the heart, but its functional role has not been elucidated.Wedeterminewhether selective
NOD1 activation modulates cardiac function and Ca2+ signalling.
Methods
and results
Mice were treated for 3 days with the selective NOD1 agonist C12-iE-DAP (iE-DAP), and cardiac function and Ca2+
cycling were assessed. We found that iE-DAP treatment resulted in cardiac dysfunction, measured as a decrease in
ejection fraction and fractional shortening. Cardiomyocytes isolated from iE-DAP-treated mice displayed a decrease
in the L-type Ca2+ current, [Ca2+]i transients and Ca
2+ load, and decreased expression of phospho-phospholamban,
sarcoplasmic reticulum-ATPase, and Na+-Ca2+ exchanger. Furthermore, iE-DAP prompted ‘diastolic Ca2+ leak’ in
cardiomyocytes, resulting from increased Ca2+ spark frequency and RyR2 over-phosphorylation. Importantly, these
iE-DAP-induced changes in Ca2+ cycling were lost in NOD12/2 mice, indicating that iE-DAP exerts its actions
through NOD1. Co-treatment of mice with iE-DAP and a selective inhibitor of NF-kB (BAY11-7082) prevented
cardiac dysfunction and Ca2+ handling impairment induced by iE-DAP.
Conclusion Our data provide the first evidence that NOD1 activation induces cardiac dysfunction associated with excitation–
contraction coupling impairment throughNF-kB activation and uncover a newpro-inflammatory player in the regulation
of cardiovascular function.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords NOD1 † Ca2+ handling † Ca2+ sparks † Cardiac dysfunction † NF-kB † Innate immune system
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide.
Cardiac dysfunction, cell death, and augmented fibrosis are common
hallmarksof severalCVDs, including heart failure anddiabetic cardiomy-
opathy. Inflammation is now recognized as an important contributor to
different manifestations of CVD.1 Indeed, extensive literature supports
the notion that pro-inflammatory cytokines released in response to
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heart damage contribute to pathological cardiac remodelling.2–5
However, it is unclear whether myocardial inflammatory response is
harmonized after cardiac injury.
A current view in the field suggests that receptors of the innate
immune system are central players in host response after cardiac
damage.6–8 Toll-like receptors (TLRs) are the best characterized med-
iators of the innate immune response in the cardiovascular system. In
heart, sustained activationof TLRs induces deleterious cardiac remodel-
ling,9 whereas TLR deletion reduces infarct size in murine models.10,11
More recently, other receptors of the innate immune system, such as
nucleotide-binding oligomerization domain-like receptors (NLRs),
have been implicated in CVDs, including atherosclerosis, dilated cardio-
myopathy, and ischaemia/reperfusion injury.4,12,13
Nucleotide-binding oligomerization domain containing 1 (NOD1) is
anNLR familymember involved in host defense that takes part in the re-
sponse against certain pathogens by regulating the inflammatory re-
sponse.14,15 NOD1 is a cytosolic receptor that, upon activation,
undergoes a conformational change that allows the recruitment and ac-
tivation of receptor-interacting protein 2 (RIP-2). RIP-2 binds to nuclear
factor kB (NF-kB) which then translocates to the nucleus to trigger the
expression of pro-inflammatory mediators.16,17 NF-kB is a key factor in
inflammatory signalling andmediates themajorityof theeffects following
NOD1 activation; indeed, the selectivity and potencyofNOD1 agonists
are frequently evaluated by their ability to activateNF-kB.16,18 NOD1 is
involved inmany human pathologies including diabetes and cancer;19–21
however, its role and relevance in the cardiovascular system are less
understood. NOD1 can mediate the inflammatory response in vascular
smooth muscle,22,23 and recently we demonstrated NOD1 expression
in murine heart, fibroblasts, and cardiomyocytes.24 Although treatment
of mice with the selective NOD1 agonist C12-iE-DAP induced an in-
crease in pro-inflammatory and apoptotic responses,24 its functional
role has not been addressed.
Cardiac function and Ca2+ homeostasis are closely coupled in
the heart. Cardiac contraction is tightly regulated by changes in intracel-
lular calcium levels. Ca2+ is a key mediator of electrical activation, ion
channel gating, and excitation-contraction coupling (EC coupling). EC
coupling is initiated by an action potential that fires a small influx of
Ca2+ via sarcolemmal L-type Ca channels (ICaL) that trigger a large
release of Ca2+ from the sarcoplasmic reticulum (SR) by ryanodine
receptors (RyR2),
25,26 increasing the intracellular Ca2+ concentration,
[Ca2+]i. This rise in cytosolic Ca
2+ results in the activation of the myo-
filaments to produce cell contraction. After contraction, Ca2+ is
removed from the cytosol mainly by two mechanisms: (i) Ca2+ uptake
by the SR-ATPase (SERCA) and (ii)Na+/Ca2+ exchanger (NCX) activa-
tion that drives Ca2+ to the extracellular medium. SERCA activity is
modulated by phospholamban (PLB). PLB inhibits the function of
SERCA in the unphosphorylated state, but once PLB is phosphorylated,
it unbinds from SERCA, which results in Ca2+ uptake to the SR.
Asmentioned earlier, during cardiac ECcoupling,Ca2+ entry through
ICaL serves as trigger of SR-Ca
2+ release. The transient increase of
[Ca2+]i is due to the summation of elementary Ca
2+ release events
termed Ca2+sparks. Ca2+sparks were first defined at the beginning of
the 1990s and reflect the in situ activity of RyR2.
27 Enhanced Ca2+sparks
in quiescent cells may indicate an abnormal diastolic Ca2+ leak that is
usually associated with certain acquired or inherited CVDs. Catechola-
minergic polymorphic ventricular tachycardia (CPVT) is an example of
an inherited disease associated with an augmented frequency of Ca2+-
sparks that is directly involved in the generation of arrhythmias.28,29
Heart failure is an acquired CVD linked to abnormal diastolic Ca2+
leak.30,31 Furthermore, certain pro-inflammatory cytokines such as
cardiotrophin-1, which are involved in some CVDs, may induce pro-
arrhythmogenic effects by increasing the occurrence of Ca2+sparks.32
Using the selectiveNOD1agonist,C12-iE-DAP (iE-DAP),we studied
the role of NOD1 activation on cardiac function and Ca2+ homeosta-
sis.18,33,34 Our findings provide the first evidence that NOD1 activation
induces a decrease in cardiac contraction in mice, associated with EC
coupling impairment, mediated by NF-kB activation. Our data reveal a
new pro-inflammatory player in the cardiac system since NOD1 might
play an important role in the regulation of cardiac function through
modulation of Ca2+ handling.
2. Methods
2.1 Animal care and cell isolation
The studywas conducted following recommendationsof the SpanishAnimal
Care and Use Committee, according to the guidelines for ethical care of ex-
perimental animals of the European Union (2010/63/EU). NOD1-deficient
mice (NOD12/2) on a B6 (C57BL6/J) background have been described.35
B6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA).Wild-type littermates were employed as a control. RT–PCR analysis
of NOD1 expression in wild-type and NOD12/2 mice confirmed the
absence of signal in NOD1-deficent mice (see Supplementary material
online, Figure S1). Ventricular cardiomyocytes frommalemicewere isolated
using standard enzymatic digestion.36 Briefly,micewere heparinized (4 U/g IP)
and injected with ‘buprenorphine’ (0.01 mg/kg), and were anaesthetized
30 min later with sodium pentobarbital (50 mg/kg). The hearts were
excised and suspended on a Langendorff perfusion apparatus, the ascending
aorta was cannulated, and a retrograde perfusion was initiated. The hearts
were perfused for 2–3 min at 36–378C with a standard calcium-free
Tyrode’s solution containing 0.2 mM EGTA, and then for 3–4 min with
the same Tyrode’s solution containing collagenase type II (Worthington)
and 0.1 mM CaCl2. The hearts were removed from the Langendorff appar-
atus, and the ventricles were finely chopped into small pieces and gently
stirred for 3 min in standard Tyrode’s solution containing 0.1 mM CaCl2.
Cell suspensions were filtered through a 250 mm nylon mesh, pelleted by
centrifugation for 3 min at 20 g, and suspended in Tyrode’s solution contain-
ing 0.5 mM CaCl2. Cells were centrifuged as before and suspended in a
storage solution containing 1 mM CaCl2. Tyrode’s solution contained
(in mM): 140 NaCl, 4 KCl, 1.1 MgCl2, 10 HEPES, 10 glucose; pH ¼ 7.4
with NaOH.
2.2 Treatments
Mice were treated for 3 days with 3.3 mg/kg of C12-iE-DAP: Lauroyl-
g-D-glutamyl-meso-diaminopimelic acid (iE-DAP), vehicle (Veh.), 3.3 mg/
kg of iE-Lys or 3.3 mg/kg of iE-DAP plus 2.5 mg/g of BAY 11–7082 (BAY)
by daily IP injection. The vehicle-injected group was the same for iE-DAP,
iE-Lys, and iE-DAP + BAY11-7082 (,0.01% DMSO), and the volume
injected was 0.1 mL in all cases. iE-DAP (Invivogen) is a selective NOD1
agonist with significant cell membrane permeability and high potency.18,33,34
iE-Lys (Invivogen) is an inactive analogue of NOD1. BAY11-7082 (Calbio-
chem) was employed to selectively block the NF-kB pathway.37–39
2.3 Echocardiography recording
M-mode echocardiography was employed to analyse cardiac function. Mice
were anaesthetizedwith 1.5% isoflurane gas, and animals were placedon the
Integrated Rail System and Mouse Handling Table (VisualSonics, Toronto,
Canada) allowing simultaneous acquisition of temperature data (378C was
maintained with the integrated heating pad). The chest of the mouse was
carefully shaved, and warm ultrasound transmission gel was employed to
permit optimal image quality. Mouse hearts were studied by echocardio-
graphy over time, using a high-frequency micro-ultrasound system
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(Vevo 770, VisualSonics). Parasternal short-axis view images of the heart
were recorded using a 30-MHz RMV scan head in a B-mode to allow
M-mode recordings by positioning the cursor in the parasternal short-axis
view perpendicular to the interventricular septum and posterior wall of
the left ventricle. Heart rate, left-ventricle ejection fraction, fractional short-
ening, left-ventricle end-systolic diameter, left-ventricle end-diastolic diam-
eter, systolic volume, and diastolic volume were determined using the
on-site software cardiac package (VisualSonics).
2.4 Intracellular calcium imaging
[Ca2+]i transients and Ca
2+ sparks were recorded in intact myocytes previ-
ously loaded with the fluorescent Ca2+ dye (Fluo-3AM, 5 mmol/L) and
under control Tyrode’s solution perfusion. Experiments were performed
at room temperature (20–238C). To obtain [Ca2+]i transients, cells were
electrically excited at 2 Hz by field stimulation using two parallel Pt electro-
des. SpontaneousCa2+ sparkswere obtained in quiescent cells after [Ca2+]i
transient recordings. SR Ca2+ load was estimated by rapid caffeine applica-
tion (10 mM). Cells were excited for 1 min before caffeine addition.
Images were obtained with confocal microscopy (Meta Zeiss LSM 710,
×40 oil immersion objective with a 1.2 NA) by scanning the cell with an
argon laser every 1.54 ms. Fluo-3AM was excited at 488 nm, and emitted
fluorescence was collected at .505 nm. Data analysis was performed
with homemade routines using IDL software (Research System Inc.).
Images were corrected for background fluorescence. The fluorescence
values (F)werenormalized by the basal fluorescence (F0) toobtain thefluor-
escence ratio (F/F0). Ca
2+ sparks were detected using an automated detec-
tion system and using a criterion that discriminated the detection of false
events while detecting most Ca2+ sparks.40
2.5 ICaL recording
Recording of L-type Ca2+ current (ICaL) was performed at room tempera-
ture (22+ 28C) using the whole-cell configuration of the patch clamp tech-
nique.Thepatchpipette resistancewas1.0–1.2 MV. ICaLwasrecordedusing
an Axopatch 200B (Axon Instruments). Current traces were digitized using
Digidata 1322A and analysed using pClamp8 software (Axon Instruments).
From a holding potential of 250 mV, voltage pulses (duration 300 ms)
between 240 to +60 mV (with 10 mV steps) were applied at a frequency
of 0.2 Hz. Ca2+ currents were normalized with cell capacitance to obtain
current density. Membrane capacitance (Cm) was elicited by applying
+10 mV voltage steps from 260 mV, and Cm was calculated according to
the equation:
Cm = tcI0
DEm[1− (I1/I0)]
where tc is the time constant of themembrane capacitance, I0 themaximum
capacitance current value, Em the amplitude of the voltage step, and I the
amplitude of the steady-state current. The extracellular solution for ICaL
recordings contained (in mM): 140 NaCl, 1.1 MgCl2, 5.4 CsCl, 10 glucose,
5HEPES, 1.8CaCl2; pHadjusted to7.4withNaOH.The intracellular record-
ing pipette solution contained (in mM): 100 CsCl, 20 TEACl, 5 EGTA, 10
HEPES, 5 Na2ATP, 0.4 Na2GTP, 5 Na2 creatine phosphate, 0.06 CaCl2;
pH adjusted to 7.4 with CsOH.
2.6 Western blot analysis
Cardiomyocytes were homogenized in a buffer containing (in mM): 50 Tris,
320 sucrose, 1 DTT, and protease/phosphatase inhibition cocktail (Sigma-
Aldrich). Homogenates were centrifuged at 13 000 g for 15 min at 48C,
and cleared supernatants were used for immunoblotting. Proteins were
separated on SDS–PAGE gels and then transferred to PVDF membranes.
Membraneswereblockedwith5%BSAand incubatedovernightwith the fol-
lowing primary antibodies: SERCA2a, phospho-PLB (Ser16), phospho-PLB
(Thr17) and PLB, phospho-RyR2 (Ser2815), phospho-RyR2 (Ser2808)
(Badrilla Ltd.), RyR2 (Affinity Bioreagents), NCX (Swant antibodies), and
GAPDH (Ambion). Membranes were then incubated with peroxidase-
linked secondary antibodies (1:5.000) in 2% BSA for 60 min at room tem-
perature. Immunoreactive bands were detected using the AmershamTM
ECLTM Protein Detection System.
2.7 Statistics
Data arepresented asmean+ SEM. Statistical analysis on the numberof iso-
lated cells/sampleswascarriedoutusing anestedANOVA, andpost hoc com-
parisons were performed by Bonferroni’s test. All statistical analyses were
made using the SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). Significance
was assumed when P, 0.05.
3. Results
3.1 NOD1 activation induces cardiac
dysfunction and impairment in EC coupling
C12-iE-DAP(iE-DAP) is awidely used selective agonist ofNOD1.18,33,34
We evaluated whether iE-DAP administration in mice was detrimental
to cardiac function. Compared with vehicle-treated mice, ejection frac-
tion, fractional shortening, and systolic volume were all decreased in
mice treated for 3 days with iE-DAP (Table 1). However, heart rate, left-
ventricle end-diastolic and end-systolic diameter, and also heart weight:
body weight ratio, were unaffected by iE-DAP treatment (Table 1).
Since cardiac function and Ca2+ homeostasis are closely coupled in
the heart, we investigated whether the reduced cardiac function
induced by iE-DAP was associated with an impairment of EC coupling.
ICaL is a key player in cardiac EC coupling, chiefly through its ability to
trigger [Ca2+]i transients.
26 Using the patch clamp technique in the
whole-cell configuration, we recorded ICaL in myocytes isolated from
vehicle or iE-DAP-treated mice. Average ICaL density from 0 to
+40 mV was significantly reduced (P, 0.05) in iE-DAP-treated mice
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Cardiac parameters collected after M-mode ultrasound evaluation of mice
HW (mg) BW (g) HR (bpm) EF (%) FS (%) LVESD (mm) LVEDD (mm) SV (mL) DV (mL) n
Vehicle 231.3+7.1 25.9+0.7 368.3+14.3 72.6+5.5 39.9+5.4 1.9+0.3 3.1+0.2 11.4+4.5 47.6+4.9 6
iE 226.6+13.3 25.5+0.9 396.0+22.0 47.9+4.0*** 28.5+3.9** 2.5+0.3 3.6+0.2 21.9+3.3** 56.4+6.2 4
iE + BAY 218.7+33.8 26.4+0.9 389.5+42.3 67.1+8.5## 36.1+6.6## 2.1+0.3 3.4+0.1 12.9+2.2## 46.1+4.2 4
Data are mean+ SEM.
HW, heart weight; BW, body weight; HR, heart rate; EF, left-ventricle ejection fraction; FS, fractional shortening; LVESD, left-ventricle end-systolic diameter; LVEDD, left-ventricle
end-diastolic diameter; SV, systolic volume; DV, diastolic volume.
**P, 0.01, ***P, 0.001 vs. vehicle (Veh.); ##P, 0.01 vs. iE (iE ¼ 3.3 mg/kg iEDAP-treatedmice for 3 days, iE + BAY ¼ 3.3 mg/kg iEDAPplus 2.5 g/kg BAY11-7082 treatedmice for 3 days).
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compared with vehicle-treated counterparts (Figure 1A). Moreover,
iE-DAP significantly reduced the maximal ICaL peak density obtained
at +10 mV vs. vehicle (–5.3+0.5 pA/pF, n ¼ 9 in iE-DAP vs. 28.2+
0.7 pA/pF, n ¼ 14 in vehicle P, 0.05). Notably, cardiomyocytes iso-
lated from mice treated with the inactive analogue of iE-DAP, iE-Lys,
exhibited similar values of ICaL density to the vehicle group (Figure 1A).
The diminution on ICaL induced by iE-DAP treatment can be related
to changes in the ICaL inactivation curve. Indeed, cardiomyocytes
obtained from iE-DAP-treated mice exhibited a shift in the voltage
dependence of ICaL inactivation towards more negative values; the
voltage of half-maximal inactivation was (V50) 219.8+ 1.8 mV in
vehicle and 226.5+ 1.9 mV in iE-DAP group (P, 0.05; see Supple-
mentary material online, Figure S2A). Importantly, no changes in the
mRNA expression of the molecular correlate of ICaL, Cav 1.2, were
detected between groups (see Supplementary material online,
Figure S2B).
Subsequently, [Ca2+]i transients electrically evoked by field stimula-
tion at 2 Hz were recorded by confocal microscopy. An example of a
line-scan image taken from a cardiomyocyte isolated from vehicle-,
iE-DAP-, or iE-Lys-treated mice is shown in Figure 1B (upper panels).
Cardiomyocytes obtained from iE-DAP-treated mice exhibited a de-
crease in the [Ca2+]i transient amplitude together with a slower time
constantof [Ca2+]i transient decay (Tau), aswell as a significant decrease
in cell contraction, compared with the vehicle group (Figure 1B lower
panels). In contrast, [Ca2+]i transient properties and cell contraction
were not affected by iE-Lys administration (Figure 1B, lower panels).
To examine whether the reduced [Ca2+]i transients detected in the
iE-DAPgroupwererelated tochanges in theSRCa2+ load,wemeasured
caffeine-evoked [Ca2+]i transients in cardiomyocytes isolated fromboth
groups. Compared with vehicle-treated mice, caffeine-evoked [Ca2+]i
transients were reduced in the iE-DAP-treated group (Figure 1C, left
panel) together with significantly slower rates of decay (Figure 1C, right
Figure 1 Short-term treatment of mice with iE-DAP induces a selective impairment in EC coupling. Mice were injected IP for 3 days with 3.3 mg/kg of
C12-iE-DAP (iE-DAP), with 3.3 mg/kg of iE-Lys (inactive analogue of iE-DAP), or with vehicle (Veh.). (A) I-V relationships ICaL in cardiomyocytes isolated
from vehicle (n ¼ 12 cells/4 mice), iE-DAP-treated mice (n ¼ 9 cells/4 mice), and iE-Lys (n ¼ 19 cells/3 mice). (B) Upper panels illustrate a representative
exampleof line-scan confocal imagesobtained in cells fromvehicle (left), iE-DAP-treatedmice (middle), and iE-Lys-treatedmice (right). Lowerpanels show the
mean values of peak fluorescence [Ca2+]i transients (F/F0, left), decay time constant (Tau, middle), and cell contraction (%, right) obtained in vehicle (n ¼ 19
cells/5 mice), iE-DAP (n ¼ 27 cells/4 mice), and iE-Lys group (n ¼ 22cells/3 mice). (C)Histograms represent themean values of caffeine-evoked [Ca2+]i tran-
sients amplitude represented as F/F0 (left) and its decay time constant (right) obtained in vehicle (n ¼ 15 cells/3 mice), iE-DAP (n ¼ 16 cells/3 mice), and iE-Lys
conditions (n ¼ 27 cells/3 mice). Results show mean+ SEM. *P, 0.05, **P, 0.01 vs. vehicle.
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panel). As expected, Ca2+ load and time of decay of caffeine-evoked
[Ca2+]i transients were unaffected by iE-Lys administration (Figure 1C).
The observed iE-DAP-induced deceleration in the decay time of
[Ca2+]i transients may be linked to an impairment in SERCA and/or
PLB expression. Thus, we analysed the phosphorylation status of PLB
(P-PLB) at serine16 (mediatedbyPKAactivation) and threonine17 (spe-
cific site for CaMKII activation), and also SERCA protein expression, in
homogenates obtained from cardiomyocytes isolated from vehicle-
and iE-DAP-treated mice. Results showed that both phosphorylation
of PLB at ser16 (Figure 2A) and SERCA expression (Figure 2C) were
decreased in the iE-DAP group compared with vehicle-treated mice.
In contrast, phosphorylation of PLB at threonine 17 was unchanged
between groups (Figure 2B).
Since SERCA function (k SERCA) can be assessed systematically from
the decay rates of the systolic and caffeine-evoked Ca transients,41 we
calculated k SERCA by subtracting the rate constant of decay of the
caffeine-evoked transient from that of the systolic Ca2+ transients.
We found that k SERCA was 100+ 0.1% (n ¼ 5) in vehicle and
77.7+ 0.1% (n ¼ 6) in iE-DAP group (P, 0.001), supporting the idea
that iE-DAP administration induces a decrease in the SERCA function.
On other hand, the decay time of caffeine-evoked [Ca2+]i transients
were increased in the iE-DAP-treated group (Figure 1C, right panel), sug-
gesting an impairmentof theNa+/Ca2+exchange (NCX) function.Thus,
we investigated whether the expression of NCX was affected by the
NOD1 agonist. As shown in Figure 2D, NCX protein levels were signifi-
cantly decreased in the iE-DAP group vs. vehicle (P, 0.05).
Collectively, these data indicate that short-term iE-DAP treatment
induces cardiac dysfunction by compromising the efficiency of EC coup-
ling by decreasing ICaL, [Ca
2+]i transients, and Ca
2+ load, and also by
impairing PLB function and down-regulating SERCA and NCX. Add-
itionally, NOD1 expression was unchanged in cardiomyocytes after
iE-DAP administration (data not shown). To evaluate whether NOD1
activation impairs the Ca2+ handling in isolated cardiomyocytes, we
incubated cells obtained from hearts of wild-type mice with 40 mg/mL
iE-DAP for 1–2 h and [Ca2+]i transient properties and cell contraction
were determined. Results showed that cells incubated with iE-DAP
exhibited a decrease in the [Ca2+]i transient amplitude (Figure 3A) to-
gether with a slower time constant of [Ca2+]i transient decay (Tau;
Figure 3B), as well as a significant reduction in cell contraction
(Figure 3C), compared with vehicle-treated cells.
Figure 2 iE-DAP treatment promotes a decrease in SERCA and NCX levels and PLB phosphorylation at serine 16. (A) and (B) Immunoblots of phos-
phorylated phospholamban (P-PLB) at ser16 or thr17 and total PLB, and the corresponding mean values displayed in histograms obtained in vehicle and
iE-DAP-treated mice. Representative blots of SERCA/GAPDH (C) and NCX/GAPDH (D) obtained from animals treated with iE-DAP or vehicle. Below,
histograms summarize the mean data. Vehicle (n ¼ 3 samples/3 mice) and iE-DAP group (n ¼ 3 samples/3 mice). Results showmean+ SEM (band ratio)
expressed as percentage vs. vehicle. *P, 0.05 vs. vehicle.
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3.2 NOD1 activation induces SR-Ca21 leak
Since diastolicCa2+ leak is closely associatedwith SR-Ca2+ load decline,
we analysed Ca2+ spark frequency and properties to measure spark-
mediated Ca2+ leak.28,42 An example of a line-scan confocal image of
a cardiomyocyte taken from vehicle- or iE-DAP-treated mice is
shown in Figure 4A. A significantly higher frequency of Ca2+ sparks
was observed in cardiomyocytes taken from iE-DAP-treatedmice com-
pared with cardiomyocytes obtained from vehicle controls (Figure 4B).
A comparison of the properties of the Ca2+ sparks showed that the
amplitude was significantly lower in cardiomyocytes taken from
iE-DAP-treated mice compared with those obtained from vehicle-
treated mice (Figure 4C). This reduction in amplitude in cells isolated
from iE-DAP-treated mice was due largely to a significant increase
(39%, see Supplementary material online, Table S1) in the population
of events with peaks around 1.3 (F/F0), with a concomitant reduction
of Ca2+ sparks with higher (above 1.5 F/F0) amplitudes, as shown by
histogram distribution (see Supplementary material online, Figure S3A).
In contrast, the average duration and width of Ca2+ sparks were un-
changed between groups (Figure 4C). Similarly, histogram distributions
of Ca2+ spark durations and widths were comparable in cells isolated
from iE-DAP- and vehicle-treated mice (see Supplementary material
online, Figure S3B and C ). Calculation of the overall spark-mediated
Ca2+ leak gave an increase of 4.7-fold after iE-DAP treatment (see
Supplementary material online, Figure S4). Thus, cardiomyocytes isolated
from iE-DAP-treated mice have increased Ca2+ leak that is derived
mainly from Ca2+ spark release. Furthermore, Ca2+ spark frequency was
unchanged by iE-Lys administration (1.6+0.4 sparks s21 100 mm21 n¼
9/N¼ 3 in vehicle, 6.4+1.4 sparks s21 100 mm21 n¼ 16/N¼ 3 in
iE-DAP, and 1.4+0.5 sparks s21 100 mm21 n¼ 12/N¼ 3 in iE-Lys
group). Ca2+ spark properties were also unchanged by iE-Lys treatment
(see Supplementary material online, Figure S5).
Next, we analysed whether the increased Ca2+ sparks detected in
the iE-DAP group impaired the resting cytoplasmic [Ca2+]i. Results
showed that the intracellular [Ca2+]i measured using Fura-2 (R340/
R380) was significantly higher in cardiomyocytes isolated from
iE-DAP-treated mice compared with equivalent vehicle-treated mice
(see Supplementary material online, Figure S6).
As described above, Ca2+ spark recordings reflect the in situ activity
of RyR2.
27 Since Ca2+ spark frequency data pointed to augmented
RyR2 activity following iE-DAP treatment, we measured phosphoryl-
ation of RyR2 at ser2808 (site for mainly PKA activation) and ser2815
(site for CaMKII activation). Results from immunoblotting showed that
ser2808 phosphorylation of RyR2 was significantly increased after
iE-DAP treatment (Figure 4D), whereas ser2815 phosphorylation of
RyR2 was unchanged (Figure 4E).
Taken together, these results confirm that iE-DAP induces diastolic
Ca2+ leak in isolated cardiomyocytes, resulting from increased Ca2+
spark frequency that can contribute to rise the resting cytoplasmic
[Ca2+]i.
3.3 iE-DAP exerts a selective effect on EC
coupling
To corroborate the selectivity of iE-DAP for Ca2+ handlingmodulation,
we used cardiomyocytes isolated from NOD1-deficient mice
(NOD12/2). We found that iE-DAP administration resulted in similar
mean values of ICaL density at all voltages tested (Figure 5A), [Ca
2+]i tran-
sient properties (Figure 5B, left and central panels), cell contraction
(Figure 5B, right panel), and Ca2+ load (Figure 5C), as well as comparable
values rates of decay of Ca2+ load (Figure 5D) to those obtained in
NOD12/2 mice treated with vehicle. Moreover, Ca2+ spark frequency
and the characteristics of Ca2+ sparks were also comparable between
the two groups (Figure 5E, see Supplementarymaterial online, Figure S7).
Thus, the lack of an effect of iE-DAP in NOD12/2 mice to induce
changes in EC coupling supports the selectivity of iE-DAP on Ca2+
signalling.
3.4 NF-kB mediates iE-DAP-induced
changes in EC coupling and cardiac function
Since we previously showed that iE-DAP treatment induces specific
NF-kB activation in cardiac tissue and isolated cardiomyocytes,24 we
assessed whether NF-kB activation could mediate the effect of
iE-DAP on Ca2+ dynamics. To do this, we employed the selective
NF-kB inhibitor, BAY11-7082 (BAY).37–39 In comparison with mice
treated with iE-DAP alone, isolated cardiomyocytes from mice
treated for3dayswith iE-DAPplusBAYhad similar ICaL values tovehicle-
treated mice (Figure 6A). Moreover, co-treatment with BAY abrogated
the iE-DAP-induced effects on amplitude anddecay timeof [Ca2+]i tran-
sients, aswell as cell contractionparameters (Figure6B).Additionally, im-
munoblotting of cardiomyocytes demonstrated that co-treatment with
BAY prevented both the iE-DAP-induced decrease in SERCA protein
expression and PLB phosphorylation at ser16 (Figure 6C).
In accord with these changes, caffeine-evoked [Ca2+]i transients
in cardiomyocytes obtained after co-treatment of mice with iE-DAP
plus BAY were comparable to those obtained from vehicle-treated
mice, recovering the loss induced by iE-DAP treatment alone
(Figure 7A, left panel). Also, both the increase in the rate of decay of
caffeine-evoked [Ca2+]i transients induced by iE-DAP (Figure 7A, right
panel) and the occurrence of Ca2+ sparks (Figure 7B, left panel) were
normalized in the presenceof BAY.Additionally, the iE-DAP-induced in-
crease in the phosphorylation of RyR2 on ser2808was abolished inmice
co-treated with BAY (Figure 7B, right panel) and is consistent with the
Ca2+ sparks recordings.
Figure 3 Cardiomyocytes treated with iE-DAP for 1–2 h showed
altered [Ca2+]i transients and cell contraction parameters. Histograms
represent the mean values of peak fluorescence [Ca2+]i transients
(F/F0,A), decay timeconstant (Tau,B), andcell contraction (%,C)obtained
in vehicle-treated cells (n¼ 13 cells/3 mice) and cells treated for 1–2 h
with 40 mg/mL iE-DAP (n¼ 12 cells/3 mice). *P, 0.05 vs. vehicle.
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Finally, co-treatment of BAYplus iE-DAP prevented the depressed
cardiac function induced by iE-DAP administration alone (Figure 7C
and Table 1). Taken together, these studies support the concept
that the NF-kB pathway underlies the iE-DAP-induced effect on
both cardiac dysfunction and impairment in cardiomyocyte Ca2+
handling.
4. Discussion
Our study provides the first direct evidence that selective activation of
the innate immune receptor NOD1 results in cardiac dysfunction
related to EC coupling impairment mediated through NF-kB signalling.
The innate immune system acts as a ‘first warning response’ to patho-
gens, infection, or organ injury. The best described mediators of the
innate immune system are TLRs and NLRs. Both receptor families
contain pattern recognition motifs that distinguish between self and
non-self, by recognizing pathogen molecular motifs or endogenous
host material derived from cellular injury/death. Cardiac damage
activates some of these receptors to induce a protective response
for tissue repair.43–45 However, sustained activation of the innate
immune system frequently results in maladaptive responses and leads
to an increase in pro-inflammatory cytokines levels, which promote
pathological cardiac remodelling.45 Accordingly, up-regulation of TLR
activity induces cardiac damage while mutations or targeted disruption
of TLRs reduce infarct size, preventing cardiac dysfunction induced by
ischaemia/reperfusion or myocardial infarction, and boost the stability
atherosclerotic lesions.11,46–49
In addition to TLRs, NLRs are also cytosolic receptors of the innate
immune system that play an important role in regulating the inflamma-
tory response.22 Recently, several studies have attributed roles for
these mediators in CVDs; in particular, the NLR NLRP3 has been
Figure 4 Frequency of Ca2+ sparks and phosphorylation of RyR2 are enhanced in cardiomyocytes isolated from iE-DAP-treated mice. (A) Example of
line-scan images of Ca2+ spark recordings obtained in a myocyte isolated from vehicle and iE-DAP-treated mice. (B) Average data of Ca2+ sparks occur-
renceobtained inboth groups. (C )MeanvaluesofCa2+ sparksproperties; peak (left panel), duration (middlepanel), andwidth (right panel) obtained in cells
isolated fromvehicle (n ¼ 9 cells/3 mice) and iE-DAP-treatedmice (n ¼ 16 cells/3 mice). Representative immunoblots of phosphorylatedRyR2 in ser2808
(panel D) or ser2815 (panel E) vs. total RyR2, and the corresponding mean values obtained in vehicle and iE-DAP group (n ¼ 3 samples/3 mice of each
group). Histograms show the mean+ SEM (band ratio) expressed as percentage vs. vehicle. *P, 0.05 vs. vehicle.
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demonstrated to mediate pathological processes including atheroscler-
osis and dilated cardiomyopathy.4,12,13 NOD1 is a member of the NLR
family that is expressed ubiquitously. NOD1 regulates the inflammatory
response in vascular smoothmuscle,22 and long-term treatment ofmice
with selective NOD1 agonists promotes vascular complications includ-
ing coronary arteritis and valvulitis.50 While NOD1 is expressed in
murine cardiomyocytes,24 its functional role in the heart has not yet
been established.
In the present study, we found that NOD1 activation promotes a sig-
nificant decrease in cardiac function, a feature shared by the majority of
CVDs including heart failure, diabetic cardiomyopathy, and ischaemia–
reperfusion injury. Moreover, cardiac dysfunction induced by adminis-
tration of theNOD1 agonist iE-DAPwas associatedwith an impairment
in EC coupling in isolated murine cardiomyocytes; specifically, cardio-
myocytes isolated from iE-DAP-treated mice displayed lower [Ca2+]i
transients amplitude compared with vehicle-treated counterparts.
This effect could be due to modulation of (i) Ca2+ current, (ii) RyR2
activity, (iii) and/or SR- Ca2+ load.
First, ICaL densitywas significantly diminished after iE-DAPadministra-
tion. Since ICaL is the main trigger of SR-Ca
2+ release via Ca2+-induced
Ca2+ release (CICR), ICaL decline can be responsible, at least in part, for
the decrease of [Ca2+]i transients induced by iE-DAP administration
(Figure 1). iE-DAP treatment also induces a slower decay time of
[Ca2+]i transients, and this effect can be correlated with changes in
the Ca2+ SR-uptake. Accordingly, iE-DAP provoked a decrease of
SERCA expression together with a decrease of PLB phosphorylation
at serine 16, but not at threonine 17. Importantly, in some CVD, e.g.
heart failure, depletion of [Ca2+]i transients is accompanied by
decreased SR-Ca2+ uptake due to changes in SERCA activity51,52 and
similar trends were observed in iE-DAP-treated mice.
In support of our data, Lee et al. have shown that the pro-
inflammatory mediator TNF-a induces alterations in Ca2+ handling by
decreasing SERCA expression in pulmonary vein cardiomyocytes.53
This decrease in SERCA levels impacts on the Ca2+ SR reuptake and
results in a longer decay time constant of [Ca2+]i transients.
53 Similar
EC coupling alterations have been described in experimental murine
Figure 5 iE-DAP treatment does notmodify EC coupling parameters inNOD12/2mice. (A) I-V relationships ICaL density in cardiomyocytes obtained in
NOD12/2 mice (n ¼ 15 cells/3 mice) andNOD12/2 mice treatedwith iE-DAP (n ¼ 15 cells/3 mice). (B) Histograms show themean values of peak fluor-
escence [Ca2+]i transients (left panel), decay time constant (middle panel), and cell contraction (right panel) obtained in myocytes isolated in NOD1
2/2
mice (n ¼ 17cells/3 mice) andNOD12/2mice treatedwith iE-DAP (n ¼ 22cells/3 mice). (C )Averagedataof caffeine-evoked [Ca2+]i transients amplitude
and its decay time (D) obtained in all experimental groups. (E)AveragedataofCa2+ sparksoccurrenceobtained in cardiomyocytes isolated fromNOD12/2
mice (n ¼ 17cells/3 mice) andNOD12/2mice treatedwith iE-DAP (n ¼ 22cells/3 mice).Histogramsrepresent themean+ SEMexpressedas percentage
vs. vehicle. Results show mean+ SEM.
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models of sepsis.54,55 Indeed, some bacterial cell membrane com-
ponents, including bacterial peptidoglycan-associated lipoprotein,
which participate in septic shock, induce altered [Ca2+]i transients
and cell shortening in murine cardiomyocytes.56 Moreover, additional
pro-inflammatory mediators such as IL-2 or cardiotrophin-1 may
induce arrhythmogenic activity through impairment of Ca2+ handling
in isolated myocytes.32,53,57
Secondly, Ca2+ sparks are a good indicator of the in situ activity of
RyR2. We show that iE-DAP induces an increase in the frequency of
elementary Ca2+ release, supporting the idea that iE-DAP provokes
an abnormal diastolic Ca2+ leak. The increased frequency of Ca2+
sparks also may contribute to reduce SR-Ca2+ load and systolic Ca2+
transients, increasing the resting cytosolic [Ca2+]i. Importantly, in
heart failure, the Ca2+ leak measured as Ca2+ sparks induces cardiac
arrhythmias since the increased Ca2+ release diffuses to neighbouring
RyR2 clusters leading to an induction of spontaneous Ca
2+ waves, trig-
gering cardiac arrhythmias. Notably, our results demonstrate that
NOD1 activation promotes an abnormal diastolic Ca2+ leak in cardio-
myocytes that might induce arrhythmias under pathological conditions
such as heart failure or sepsis, where an enhanced pro-inflammatory
milieu prevails. Consistent with this notion, treatment of isolated cardi-
omyocytes with the pro-inflammatory cytokine cardiotrophin-1
resulted in increased Ca2+ spark events, closely related to the
pro-arrhythmogenic effect of this mediator.58
Regarding our observations on Ca2+ spark properties, their ampli-
tude was significantly reduced after iE-DAP administration, without
alterations in their duration or width. These results can be explained
by the fact that driving force can be equivalently diminished with the
SR-Ca2+ load decreased.59,60
Finally, Our results demonstrate that iE-DAP induces a decrease of
SR-Ca2+ load measured as caffeine-evoked [Ca2+]i transients. Thus,
our data show that SERCA reduction, together with increased open
probability of RyR2 reflected by the enhanced frequency of Ca
2+
sparks induced by iE-DAP, may contribute to decrease the SR Ca2+
load, compromising systolic Ca2+ transients and decreasing cell con-
traction, and therefore cardiac function. It would be interesting to
confirm the changes in SR Ca2+ load by quantitative approaches
involving measurement of NCX current integrals.
SR Ca2+ content reflects the balance between Ca2+ uptake, influx,
and efflux mechanisms via at least four main Ca2+ handling proteins:
SERCA, RyR, ICaL, and NCX. Indeed, under physiological steady-state
conditions, one effect of a higher diastolic Ca2+ leak (proved by an
increased Ca2+ spark frequency in iE-DAP cells) would be a partial de-
pletion of SR Ca2+ content, which could be worsened by a reduced
SERCA function. Thus, the outcomewould be the reduction of theRyR-
mediated Ca2+ leak, to reach a new steady-state condition. However, a
possible mechanism involved in the preservation of SR Ca2+ load that
maintains the sustained elevation of Ca2+ spark frequency under
iE-DAP treatment might be related to the down-regulation of NCX
(Figure 2D) induced by iE-DAP. The reduction in NCX expression con-
tributes to increase resting cytosolic Ca2+ concentration (see Supple-
mentary material online, Figure S6), extruding less Ca2+ outside the
cell and favouring the reloading of the SR via SERCA at least partially, al-
though this ATPase works slower. In this line, conditional SERCA-KO
mice and pharmacological tools employed to reduce SERCA activity
(thapsigargin) have shown that the down-regulation/inhibition of
SERCA activity has minimal effects on overall SR Ca2+ content. This
can be explained by two factors: the direct relationship between SR
Ca2+ content and SERCA activity, and the linear dependence of the
amplitude of the systolic Ca2+ transient on SR Ca2+ content, which in
some cases low SR Ca2+content promotes a decrease in the systolic
SR Ca2+ efflux, thus maintaining the SR Ca2+ load. Indeed, our results
show that the amplitude of Ca2+ transients are significantly lower in
the iE-DAP group (Figure 1B); and also that iE-DAP administration
induces a decrease in the SERCA function of around 20% (K SERCA)
compared with veh. group. So, iE-DAP treatment gets SERCA
working at least at80%tomaintainSRCa2+ content at a level sufficient
that is enough to sustain spark-mediated Ca2+ leak (not below of
400 mM, which could stop the release of Ca2+ in the form of
sparks). Another key aspect is that although iE-DAP induces an increase
in Ca2+ spark number, the mean amplitude of Ca2+ sparks was signifi-
cantly lower in the iE-DAP group compared with the vehicle ones
(Figure 4C), reducing the amount of Ca2+ released as Ca2+ sparks.
It was important to validate the NOD1 agonist iE-DAP. Although the
selectivity of iE-DAP has been addressed by several studies in different
organs and cells, we verified that iE-DAP exerts a selective effect on
Ca2+ cycling in isolatedmyocytes. Accordingly,mice treatedwith the in-
active analogue of iE-DAP, iE-Lys, and NOD1-deficient mice treated
with iE-DAP, failed to modify the cardiac EC coupling parameters.
Figure 6 NF-kB activation mediates the effects induced by iE-DAP
on ICaL and [Ca
2+]i transients. (A) Bar graph representing the average
ICaL density (pA/pF) recorded at+10 mV in cardiomyocytes obtained
in iE-DAP (3.3 mg/kg IP/3 days) plus BAY (BAY, 2.5 mg/g) treated mice
(n ¼ 10 cells/3 mice). (B) Histograms illustrate the average of [Ca2+]i
transients amplitude, its decay time, and the cell contraction data
obtained in cells isolated from iE-DAP plus BAY-treated mice
(n ¼ 15 cells/3 mice). (C) Average data for SERCA (left panel) or
P-PLB at ser16 (right panel) vs. GAPDHor PLB expression, respective-
ly, from iE-DAP+BAY samples (n ¼ 3 samples/3 mice). Data repre-
senting the mean+ SEM expressed as percentage of vehicle (dotted
line).
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This selectivity strengthens the findings that NOD1 participates in the
regulation of Ca2+ handling.
Mechanistically,we showthat thedetrimental effect onCa2+handling
and cardiac function induced by iE-DAP is mediated by the NF-kB
pathway. NF-kB is a central player in the inflammatory response and
mediates many of the effects derived from NOD1 activation. The
precise role ofNF-kB in heart remains controversial since both adaptive
andmaladaptive actions have been described. Thus, early NF-kB activa-
tion following acute cardiac damage may support adaptive mechanisms
topreventpathological remodelling. In contrast, sustainedNF-kBactiva-
tion would be maladaptive by preserving the inflammatory re-
sponse.61,62 In this context, the selective blockade of NF-kB may
provide protection against ischaemia reperfusion damage, attenuating
infarct size, reducing inflammation and cell death events, and improving
cardiac function.63–65
NF-kB is involved in multiple signalling pathways related to Ca2+
homeostasis, e.g. calcineurin-NF-AT and IP3.
66,67 Our results show
that selective inhibition of NF-kB signalling with BAY completely
Figure 7 iE-DAP alters Ca2+ load, Ca2+ sparks occurrence, and cardiac contraction thoughNF-kB activation. Diagram represents the effects of NOD1
agonist in EC coupling. (A) Bar graphs representing the average of caffeine-evoked [Ca2+]i transients (F/F0) (left panel) and its decay time constant (right
panel) obtained in iE-DAP plus BAY-treated mice (n ¼ 26 cells/3 mice). (B) Left panel shows histogram summarizing the average data of Ca2+ sparks oc-
currence obtained in iE-DAP+ BAY group. Right panel illustrates the average of P-RyR2 in ser2808 vs. total expression of RyR2 obtained in iE-DAP+ BAY
mice (n ¼ 3 samples/3 mice). (C) Histogram reflects the average of cardiac ejection fraction values detected in iE-DAP + BAY-treatedmice (n ¼ 4mice).
Results show themean+ SEMexpressed as percentage of vehicle (dotted lines). (D)Diagram representing the possiblemechanisms involved in the effects
of iE-DAP inCa2+ handling. iE-DAP induces selectiveNOD1 activation, involvingNF-kB activation, andmodulates ICaL andRyR function aswell as PLB and
SERCA impairment, resulting in cardiac dysfunction. On one hand, the increased Ca2+ leak contributes to reduce the SR Ca2+ load, increasing the resting
cytosolic [Ca2+]i and compromising the systolic Ca
2+ release. On the other hand, phosphatases and phosphodiesterases (PP, PDE) may act by decreasing
the phosphorylation of PLB, contributing to decrease SR-Ca2+ load under iE-DAP administration.
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prevented the Ca2+ handling effects induced by administration of
iE-DAP (Figures 6 and 7). Supporting these data, a recent report by
Zhang et al.65 has shown that NF-kB loss of function protects against
cardiac damage by maintaining Ca2+ cycling. In this study, deletion of
the NF-kB subunit p65 was associated with augmented SR-Ca2+
release and elevated PLB phosphorylation at ser16. These results
suggest that NF-kB can modulate the Ca2+ SR uptake through PKA ac-
tivation.Consistentwith this, our results also show thatNF-kBmediates
the iE-DAP-induced effects on Ca2+ homeostasis, and blockade of the
NF-kB pathway prevents also the PKA phosphorylation effects
induced by the NOD1 agonist on PLB and RyR2.
In conclusion, our results describe a new role for NOD1 outside of
the immune setting, highlighting the importanceof thepro-inflammatory
response and its consequences on cardiac function (Figure 7D). Import-
antly, the effects of NOD1 activation in the heart share many of the fea-
tures detected in relevant CVDs, such as heart failure. In this context, in
addition to apoptotic and fibrotic events, the NOD1 agonist induces
cardiac dysfunction by Ca2+ cycling impairment; all of which are
detected in human and experimental models of heart failure. Notably,
CVDs linked to RyR2 gain of function show excessive channel activity
that is associated with cardiac arrhythmias and contractile dysfunction,
in addition to pathological cardiac remodelling. Our findings point to
NOD1 as an important regulator of both systolic and diastolic Ca2+
release, andmay provide a basis for the development of novel strategies
for therapeutic intervention of Ca2+ handling impairment in specific
CVD, such as dilated cardiomyopathy or ischaemia/reperfusion injury,
where NLR activation has been described.
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Abstract
Type 2 diabetes has a complex pathology that involves a chronic inflammatory state. Emerging evidence suggests a
link between the innate immune system receptor NOD1 (nucleotide-binding and oligomerization domain 1) and the
pathogenesis of diabetes, in monocytes and hepatic and adipose tissues. The aim of the present study was to
assess the role of NOD1 in the progression of diabetic cardiomyopathy. We have measured NOD1 protein in cardiac
tissue from Type 2 diabetic (db) mice. Heart and isolated cardiomyocytes from db mice revealed a significant
increase in NOD1, together with an up-regulation of nuclear factor κB (NF-κB) and increased apoptosis. Heart tissue
also exhibited an enhanced expression of pro-inflammatory cytokines. Selective NOD1 activation with
C12-γ -D-glutamyl-m-diaminopimelic acid (iEDAP) resulted in an increased NF-κB activation and apoptosis,
demonstrating the involvement of NOD1 both in wild-type and db mice. Moreover, HL-1 cardiomyocytes exposed to
elevated concentrations of glucose plus palmitate displayed an enhanced NF-κB activity and apoptotic profile, which
was prevented by silencing of NOD1 expression. To address this issue in human pathology, NOD1 expression was
evaluated in myocardium obtained from patients with Type 2 diabetes (T2DMH) and from normoglycaemic
individuals without cardiovascular histories (NH). We have found that NOD1 was expressed in both NH and T2DMH;
however, NOD1 expression was significantly pronounced in T2DMH. Furthermore, both the pro-inflammatory cytokine
tumour necrosis factor α (TNF-α) and the apoptosis mediator caspase-3 were up-regulated in T2DMH samples.
Taken together, our results define an active role for NOD1 in the heightened inflammatory environment associated
with both experimental and human diabetic cardiac disease.
Key words: apoptosis, cardiomyocyte, human myocardium, inflammation, nucleotide-binding and oligomerization domain 1 (NOD1), Type 2 diabetes
INTRODUCTION
Diabetes mellitus is the world’s fastest growing disease with high
rates of morbidity and mortality. A significant number of dia-
betic patients develop cardiomyopathy, mainly by presenting left
ventricular dysfunction independent of coronary artery disease
or hypertension. Diabetes is characterized by deregulated lipid
metabolism, insulin resistance, mitochondrial dysfunction and
Abbreviations: CARD, caspase recruitment domain; COX2, cyclo-oxygenase 2; db mouse, Type 2 diabetic mouse; H&E, haemotoxylin and eosin; HFD, high-fat diet; IκB, inhibitor of
nuclear factor κB; IKK, inhibitor of nuclear factor κB kinase; iEDAP, γ -D-glutamyl-m-diaminopimelic acid; IL, interleukin; NF-κB, nuclear factor κB; NH, normoglycaemic individual(s)
without a cardiovascular history; NLR, nucleotide-binding and oligomerization domain-like receptor; NOD1, nucleotide-binding and oligomerization domain 1; NOS2, NO synthase 2;
RIP2, receptor-interacting protein 2; T2DMH, patient(s) with Type 2 diabetes; TLR, Toll-like receptor; TNF-α, tumour necrosis factor α; TUNEL, terminal
deoxynucleotidyltransferase-mediated dUTP nick-end labelling; wt mouse, wild-type mouse; X-IAP, X-linked inhibitor of apoptosis.
1These authors contributed equally to the study.
Correspondence: Dr Mar´ıa Ferna´ndez-Velasco (email mvelasco@iib.uam.es or maria.fernandez@idipaz.es) or Professor Lisardo Bosca´ (email lbosca@iib.uam.es).
disturbances in adipokine secretion and signalling [1]. Myocyte
loss and development of fibrosis contribute to the cardiac dys-
function observed in diabetic patients [1,2]. In addition, diabetes
is associated with a chronic inflammatory state characterized by
increased release of pro-inflammatory mediators [3–5]. In this
context, activation of the innate immune system not only medi-
ates the host response against pathogens, but can also contribute
to insulin resistance and diabetes progression [6–9]. Accordingly,
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an increase of innate immune mediators such as Toll-like recept-
ors (TLRs) has been detected in monocytes isolated from Type 2
diabetic patients [10].
In addition to TLRs, the innate response includes a family
of cytoplasmic receptors that recognize components of micro-
organisms or abnormal/damaged host cells: the nucleotide-
binding and oligomerization domain-like receptors (NLRs) [11].
Currently, 22 members of the NLR family have been identi-
fied in humans [12–14]. Nucleotide and oligomerization do-
main 1 (NOD1) is an NLR subfamily member that, upon ac-
tivation, undergoes a conformational modification that allows
the recruitment and activation of the protein serine-threonine
kinase 2 [receptor-interacting protein 2 (RIP2)], resulting in nuc-
lear factor κB (NF-κB) activation and initiation of inflammat-
ory gene transcription. Dysregulation of NLR function has been
described in various diseases, including chronic inflammation,
autoimmunity and cancer pre-disposition [14,15]. Activation of
NOD1 signalling has been related to the progression of vascular
inflammation [16–19] and also to apoptosis [20,21]. Less inform-
ation is available on the role of NLR signalling in cardiac tissue;
however, we have reported previously that NOD1 is expressed
in the mouse heart, and NOD1 activation with the selective ag-
onist C12-γ -D-glutamyl-m-diaminopimelic acid (referred to sub-
sequently as iEDAP) induces cardiac fibrosis and apoptosis, and
also impairs cardiac function [22].
Interestingly, NOD1 has been detected in tissues involved dir-
ectly in glucose homoeostasis, such as liver, muscle and adipose
tissue [23]. Indeed, NOD1 agonists induce insulin resistance both
‘in vivo’ and ‘in vitro’ through alterations in glucose production
and clearance [7,24]. Recently, Shiny et al. [25] demonstrated that
monocytes obtained from patients with Type 2 diabetes (T2DMH)
have increased mRNA levels of NOD genes. To date, no data are
available concerning the role of NOD1 in the inflammatory re-
sponse in cardiac diseases, including those related to diabetes.
Thus, the objective of the present work was to assess the particip-
ation of NOD1 in cardiac inflammation linked to diabetes. On this
basis, we have determined NLR expression in hearts from db/db
mice (subsequently referred to as db), a rodent model for Type 2
diabetes. Moreover, to gain insight into human pathophysiology
of diabetes, we have assessed the presence of NOD1 in cardiac
tissue from T2DMH and in myocardium of normoglycaemic in-
dividuals without cardiovascular histories (NHs). Our results in-
dicate that the NOD1 pathway is up-regulated in myocardium in
both experimental and human diabetes and is associated with an
increased pro-inflammatory and apoptosis profile. Thus, NOD1
activation in the heart establishes a new paradigm for linking
NLRs to cardiac inflammation related to Type 2 diabetes.
MATERIALS AND METHODS
Ethics
All experiments on humans and mice were performed with the
approval of the Consejo Superior de Investigaciones Cientı´ficas
(CSIC) and the La Paz Hospital human ethics and animal policy
and welfare (Ref. DGG28079-37-A) following recommendations
of the Spanish and European guidelines (2010/63/EU).
Animal model
The leptin-receptor-deficient dbmice were used as a rodent model
for obesity and Type 2 diabetes; db/+ (subsequently referred to
as wt) mice were used as a wild-type group.
Chemicals
iEDAP was from InvivoGen and was used to selectively activate
NOD1. Staurosporine was purchased from Calbiochem.
Cell isolation
Ventricular cardiomyocytes were isolated from control (wt) and
diabetic (db) mice using a standard enzymatic digestion as de-
scribed previously [26].
HL-1 culture
HL-1 cells were seeded in a fibronectin/gelatin (1 mg/ml
and 0.02 %) coating matrix. Cells were maintained with
Claycomb medium (A.T.C.C.) supplemented with 10 % FBS,
2 mmol/l L-glutamine, 0.1 mmol/l noradrenaline and 1 % peni-
cillin/streptomycin. Cells were grown at 37 ◦C in an atmosphere
of 5 % CO2. Glucose plus palmitate supplementation was added
to 1 % of acid-free BSA fraction V in Claycomb medium.
NOD1 siRNA silencing
A specific siRNA (sense: 5′-CCGUCUCACGGUUAUCAGAtt-
3′; antisense: 5′-UCUGAUAACCGUGAGACGGct-3′; Ambion)
was used to silence the expression of the NOD1 gene; an equi-
valent scrambled sequence served as a control. HL-1 cells were
transfected with 100 nM of siRNA using LipofectamineTM 2000
(Invitrogen). The degree of NOD1 knockdown was determined
by a fluorescein conjugate control of siRNA and by Western
blot analysis at 24 h and 48 h after transfection. The transfec-
tion efficiency of the siRNAs was 70–80 %. Transfection with a
scrambled siRNA did not modify the NOD1 levels in vehicle and
glucose plus palmitate-treated cells.
Glucose and palmitate supplementation and drug
treatment
Palmitate stock solution was prepared in DMSO. Controls cells
were treated with vehicle (BSA and DMSO). Glucose, palmitate
and actinomycin D were from Sigma.
Preparation of total protein cell extracts
Tissues/cells were homogenized using a handheld blender in lysis
buffer [50 mmol/l Tris/HCl (pH 7.0), 320 mmol/l sucrose and
1 mmol/l DTT plus a complete protease and phosphatase inhibitor
solution (Sigma)]. The homogenate was centrifuged at 13 000 g
for 10 min at 4 ◦C, and supernatants were frozen and stored at
− 80 ◦C for Western blot analysis. Protein concentrations were
determined by the Bradford assay (Bio-Rad).
Preparation of nuclear and cytosolic protein
extracts for p65 analysis
Cardiac tissue was homogenized by 10 s sonication at 4 ◦C
in homogenization cytosolic buffer [10 mmol/l Hepes (pH 8),
666 C© The Authors Journal compilation C© 2014 Biochemical Society
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10 mmol/l KCl, 1 mmol/l EDTA, 1 mmol/l EGTA and 0.5 %
Nonidet P40]. Tissue pieces were vortex-mixed and centrifuged
at 12 000 g for 30 min. Supernatant was taken as the cytosolic
fraction. The pellet was re-suspended in 50 μl of ice-cold nuc-
lear buffer [20 mmol/l Hepes (pH 8), 0.4 mmol/l NaCl, 1 mmol/l
EDTA, 1 mmol/l EGTA and 20 % glycerol] and vortex-mixed at
4 ◦C for 30 min. After centrifugation (12 000 g at 4 ◦C for 20 min),
the supernatant (nuclear fraction) was collected. All buffers con-
tained a protease and phosphatase inhibitor cocktail (Sigma).
Western blot analysis
Equal amounts of protein (20–80 μg) were separated by
SDS/PAGE (10–12 % gel). Proteins were size fractionated, trans-
ferred on to a Hybond-P membrane (GE Healthcare) and, after
blocking with 5 % non-fat dry milk, incubated with the corres-
ponding antibodies. The blots were developed by the ECL pro-
tocol (GE Healthcare), and different exposure times were per-
formed for each blot with a charge-coupled device camera in
a luminescent image analyser (Molecular Imager, Bio-Rad) to
ensure the linearity of the band intensities. Values of densito-
metry were determined using Quantity One software (Bio-Rad).
Antibodies against NOD1, phospho-RIP2, RIP2, phospho-IKK
(inhibitor of nuclear factor κB kinase), IKK, phospho-IκBα (in-
hibitor of nuclear factor κB α), IκBα, NOS2 (NO synthase 2),
COX2 (cyclo-oxygenase 2), p65, caspase-3, BAX and X-IAP
(X-linked inhibitor of apoptosis) were purchased from the Santa
Cruz Biotechnology or the Cell Signaling Technology. An anti-
[human NOD1 (hNOD1)] antibody was purchased from R&D
Systems.
RNA isolation and reverse transcription–PCR
RNA was extracted from cells using TRI Reagent® solution
(Ambion) and 1 μg was reverse-transcribed into cDNA using
the Transcriptor first strand cDNA synthesis kit (Roche).
Then, real-time PCR was performed with this template cDNA
adding FastStart Universal SYBR Green Master (Roche) and
the specific primers in a MyIQ thermocycler (Bio-Rad). Each
sample was run in duplicate and was normalized to 18S
RNA. The replicates were then averaged and fold induction
was determined by Ct-based fold-change calculations.
Primers sequence were the following tumour necrosis factor α
(TNF-α) forward: 5′-CATCTTCTCAAAATTCGAGTGACAA-
3′; reverse: 5′-TGGGAGTAGACAAGGTACAACCC-3′; IL
(interleukin)-1β forward: 5′-GAAGCTGTGGCAGCTACCTG-
3′; reverse: 5′-GAAAAGAAGGTGCTCATGTCC-3′; IL-6 for-
ward: 5′-CTGCAAGAGACTTCCATCCAGTT-3′; reverse:
5′-GAAGTAGGGAAGGCCGTGG-3′; 18S forward: 5′-GC-
AATTATTCCCCATGAACGA-3′; reverse: 5′-AAAGGGAG-
GGACTTAATCAA-3′.
Cell death and viability detection
For detection and quantification of apoptosis, the terminal
deoxynucleotidyltransferase-mediated dUTP nick-end labelling
(TUNEL) commercial kit for cell death detection (Roche) was
used. The cell survival assay relies on the capacity of cells to re-
duce MTT (Calbiochem) to a coloured formazan in metabolically
active cells. Cardiomyocytes from both wt and dbmice suspended
Table 1 Comparison of the biochemical data from human
subjects
HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; ns, not significant.
Parameter NH (n=5) T2DMH (n=6) P value
Age (years) 41.4 +− 7.8 72 +− 2.3 P< 0.01
Weight (kg) 71.2 +− 3.3 81.9 +− 16.9 ns
Glucose (mg/dl) 84.5 +− 3.2 164.6 +− 20.5 P< 0.01
HDL-cholesterol (mg/dl) 54.5 +− 2.0 30.2 +− 3.8 P< 0.01
LDL-cholesterol (mg/dl) 111.7 +− 1.2 163.2 +− 45.5 ns
LDL/HDL-cholesterol ratio 2.7 +− 0.4 4.1 +− 0.6 P< 0.05
HbA1c (%) 4.4 +− 0.1 6.9 +− 0.7 P< 0.05
in storage solution were incubated for 2 h with 0.5 mg/ml MTT
in the dark at 37 ◦C, and then 100 μl of 50 % dimethylformamide
in 20 % SDS (pH 4.7) was added. Absorbance was measured at
595 nm. All assays were performed in triplicate.
Human specimens
Myocardial samples from six T2DMH and five NH were obtained
during autopsy procedure at the La Paz Hospital. Human cardiac
samples were taken during the forensic autopsy (post-mortem
time <48 h). Post-mortem time was defined as the estimated
time from death to autopsy. Cardiac tissues were processed rap-
idly to avoid possible deleterious changes at the cellular level.
Full informed written consent was obtained from the family
of all donors. Biochemical data of all subjects are included in
Table 1. Gross and histopathological study of hearts from NH
and T2DMH did not show any acute myocardial lesions. For his-
topathological procedures, tissues were processed by fixing in
4 % buffered formalin and embedded in paraffin wax. The dia-
betic complications registered in the autopsy history included a
patient who suffered an ictus and other individual who had acute
kidney failure.
Immunohistochemistry
Serial 5-μm-thick transverse sections of left ventricular cardiac
tissue were mounted on glass slides and allowed to dry. Sections
were stained with haemotoxylin and eosin (H&E) or deparaffin-
ized, unmasked and peroxidase-blocked by incubating in 0.1 %
H2O2 diluted in methanol, blocked in 1 % BSA and 5 % NGS
(normal goat serum) in TBS for 2 h and then exposed to anti-
NOD1 (1:100 dilution; R&D Systems), -TNF-α (1:400 dilution;
Abcam) or -caspase-3 (1:100 dilution; Cell Signaling) antibody
overnight at 4 ◦C. Antibodies were labelled with a biotinylated
streptavidin-biotin method and visualized with diaminobenzid-
ine. Slides were then counter-stained with haematoxylin before
being dehydrated, cleared and mounted. Photographs were taken
with a microscope (Olympus CX40).
Statistics
Data are presented as means +− S.E.M. Statistical significance
was assessed using a Student’s t test or ANOVA, followed by the
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Bonferroni’s test when appropriate. Differences with values of
P< 0.05 were considered statistically significant.
RESULTS
Expression of NOD1 in the myocardium of diabetic
mice
As previous evidence suggests that NOD1 can participate in
diabetes [7,27–29], we have evaluated the expression of NOD1
in the myocardium of a transgenic db mouse model. db mice
manifest several indicators common to patients with Type 2 dia-
betes, including obesity, hyperglycaemia, hyperinsulinaemia and
depressed cardiac function [30–33]. Accordingly, db mice were
significantly heavier than their wt counterparts and had increased
blood concentrations of glucose and insulin (Supplementary
Figure S1 at http://www.clinsci.org/cs/127/cs1270665add.htm).
NOD1 protein expression, detected by Western blot analysis, was
found in cardiac tissue from both db mice and corresponding wt
mice; however, expression was significantly greater in db mice
(Figure 1A, P< 0.01 compared with wt mice). Together with el-
evated NOD1 levels, cardiac tissue from db mice also exhibited
an increase in the phosphorylation of the NOD1 adapter RIP2 that
leads to NF-κB activation [34], demonstrated by increased levels
of phospho-IKK/IKK and phospho-IκBα/IκBα (Figure 1A) and
nuclear enrichment of p65 (Figure 1A, right panel). Interestingly,
hearts from db mice also contained elevated levels of NOS2
and COX2, consistent with NF-κB activation (Figure 1B). These
changes were also accompanied by significant increases in the
levels of the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β
in hearts from db mice relative to wt mice (Figure 1B).
To validate these results in a second diabetes model, we
have determined NOD1 expression in cardiac tissue from mice
subjected to a high-fat diet (HFD) to provoke obesity. Pre-
dictably, mice fed on the HFD for 12 weeks were signific-
antly heavier than chow-fed littermates and had significantly
greater levels of serum glucose and insulin (Supplementary
Figure S2 at http://www.clinsci.org/cs/127/cs1270665add.htm).
Notably, HFD-fed mice also demonstrated increased expression
of NOD1 in heart tissue compared with chow-fed littermates
(Supplementary Figure S2). Thus, in two independent models
of hyperglycaemia, NOD1 protein is elevated in cardiac tissue.
Given that cardiac apoptosis participates in the pathogenesis
of diabetes [2], and a direct relationship between NOD1 activation
and apoptosis induction has been previously established [20,21],
we next questioned whether NOD1 activation was responsible for
cardiomyocyte apoptosis. Thus, TUNEL assays were performed
on cardiac tissue, and we have measured activated caspase-3, X-
IAP and BAX protein in db and wt mice. In contrast with tissue
from wt mice, ventricular tissue from db mice contained higher
levels of the pro-apoptotic proteins caspase-3 and BAX and lower
levels of the anti-apoptotic mediator X-IAP (Figure 1C). A similar
result was obtained by TUNEL staining (Figure 1D), showing a
greater degree of DNA fragmentation in cardiac tissue from db
mice (7.7 +− 4.1 % of TUNEL-positive cells in db mice compared
with 0.9 +− 1.0 % in wt mice).
Cardiomyocytes isolated from hearts of db mice
exhibit NOD1 activation and increased apoptosis
To assess whether the pathological changes observed in the hearts
of db mice were related to changes at the level of the cardiomyo-
cyte, we have isolated cardiomyocytes from hearts of db and wt
mice and analysed the expression of NOD1. Immunostaining of
cardiomyocytes from wt and db mice revealed intense NOD1
reactivity in cardiomyocytes from db mice and reduced stain-
ing in cells from wt mice (Figure 2A). Similarly, Western blot
analysis demonstrated a 3-fold increase in NOD1 expression in
cardiomyocytes from db mice relative to controls (Figure 2B).
In addition, NF-κB activation and expression of the COX2 tar-
get gene was also significantly greater in cardiomyocytes isolated
from hearts of dbmice (Figure 2B). Furthermore, cardiomyocytes
isolated from hearts of db mice were more apoptotic, measured
as the number of TUNEL-positive cells (Figure 2C), and their vi-
ability was reduced, as determined by an MTT assay (Figure 2D).
Consequently, cardiomyocytes from dbmice had greater levels of
the pro-apoptotic proteins caspase-3 and BAX, together with re-
duced levels of the anti-apoptotic protein X-IAP (Figure 2E). Fi-
nally, to assess whether cardiomyocytes from db mice were more
sensitive to cell death/apoptosis, we have treated cardiomyocytes
from both db and wt mice with the alkaloid staurosporine to
induce apoptosis. Interestingly, staurosporine-induced apoptosis
was maximal in cells isolated from hearts of db mice, and they
also exhibited the greatest loss in cell viability (Supplementary
Figure S3 at http://www.clinsci.org/cs/127/cs1270665add.htm).
Selective stimulation of NOD1 induces activation of
NF-κB and apoptosis
Given the results described above, we next investigated whether
specific activation of NOD1 would lead to a similar inflammat-
ory profile and activation of apoptosis in mice. To do this, we
have taken advantage of the selective NOD1 agonist iEDAP
[35,36]. wt and db mice were treated daily with an intraperi-
toneal injection of iEDAP (5 μg/g of body weight), or vehicle,
over a 2-week period, and hearts were examined for activation
of NOD1. Western blot analysis of heart tissue demonstrated
that, compared with control mice, wt mice injected with iEDAP
exhibited a statistically significant increase in both phospho-
IKK/IKK and phospho-IκBα/IκBα expression and the NF-κB
target genes NOS2 and COX2 (Supplementary Figure S4A at
http://www.clinsci.org/cs/127/cs1270665add.htm) to levels com-
parable with those found in dbmice. In addition, iEDAP treatment
of db mice further increased the expression of these inflammat-
ory markers (Supplementary Figure S4A). As anticipated, ana-
lysis of TUNEL-positive nuclei in treated and non-treated mice
revealed that NOD1 activation by iEDAP increased the number
of apoptotic cells in heart tissue compared with vehicle-treated
animals (Supplementary Figure S4B). This was accentuated in
iEDAP-treated db mice. Finally, analysis of pro-apoptotic protein
expression mirrored the TUNEL analysis (Supplementary Figure
S4C) and showed that iEDAP treatment up-regulates caspase-3
and BAX, while reducing X-IAP. Collectively, these results rein-
force our findings in db mice and indicate that NOD1 stimulation
is associated with increased apoptosis and inflammatory gene
activation.
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Figure 1 Cardiac expression of NOD1, NF-κB and apoptotic pathways are enhanced in db mice
(A) Left panel shows representative immunoblots of NOD1, phospho-RIP2, RIP2, phospho-IKK, IKK, phospho-IκBα, NOS2
and COX2 in hearts from wt and db mice. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalization.
Central panel shows histograms representing the mean +− S.E.M. values, expressed as a percentage compared with wt
mice (100 %); n= 4–6 animals. Right panel shows a representative example of p65 distribution in cytosolic and nuclear
fractions in the wt and db groups. (B) Fold induction of cardiac expression of TNF-α, IL-6 and IL-1β in hearts from db
mice (shaded) relative to wt mice (white). (C) Left panel shows representative immunoblots of activated caspase-3, BAX
and X-IAP obtained from heart tissue of wt and db mice and the corresponding densitometry (right panel, n= 4). GAPDH
was used for normalization of loading. (D) Representative images of TUNEL (green) and DAPI (blue) staining in cardiac
tissue sections of db and wt mice (×40, 5 μm/slide). Mean +− S.E.M. values of TUNEL-positive cells have been added to
the images. Light transmission of TUNEL preparations point to cardiomyocytes as the main apoptotic phenotype involved.
Data are expressed as means +− S.E.M. compared with wt mice (100 %). ∗P< 0.05, ∗∗P< 0.01 and ∗∗∗P< 0.001 compared
with wt mice.
High concentrations of palmitate and glucose
induce the up-regulation of NOD1 and apoptotic
signalling in HL-1 cells
In an attempt to mimic the diabetes-like pathological micro-
environment found in vivo, we have used the HL-1 cardi-
omyocyte cell line, exposed these cells to high concentra-
tions of glucose plus palmitate (lipid-induced insulin resist-
ance model) for 48 h and assessed changes to the NOD1 sig-
nalling pathway. As expected, exposure of HL-1 cells to gluc-
ose plus palmitate resulted in lipid accumulation together with
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Figure 2 Cardiomyocytes isolated from db mice overexpress NOD1 and exhibit sustained activation of NF-κB and apop-
tosis pathways
(A) Confocal microscopy images of a representative cardiomyocyte isolated from the heart of a wt and db mouse stained for
NOD1. (B) Immunoblot analysis of NOD1 signalling. Left panel shows representative blots of NOD1, phospho-RIP2/RIP2,
phospho-IKK/IKK, phospho-IκBα/IκBα and COX2 from isolated cardiomyocytes of wt and db mice. Right panel shows the
means +− S.E.M. (n= 4 cell preparations) expressed as a percentage compared with wt mice (100 %). (C) Representative
TUNEL assay of cardiomyocytes from wt and db mice (green staining is TUNEL positive nuclei; blue corresponds to DAPI
nuclei staining). Means +− S.E.M. are represented in (D); right panel shows cell viability measured by MTT (n= 4–6 assays
per condition). (E) Representative immunoblots of activated caspase-3, BAX and X-IAP in isolated cardiomyocytes from
hearts of wt and db mice. Means +− S.E.M. are expressed as a percentage of wt mice (100 %).∗P< 0.05 and ∗∗∗P< 0.001
compared with wt mice (n= 4 cell preparations).
impairment of insulin signalling (Supplementary Figure S5 at
http://www.clinsci.org/cs/127/cs1270665add.htm). In addition,
HL-1 cells treated with glucose and palmitate showed increased
expression of NOD1, as measured by immunofluorescence (Fig-
ure 3A) and Western blot analysis (Figure 3B). Moreover, RIP2
phosphorylation and NOS2 induction were increased similarly
upon treatment (Figure 3B). Notably, siRNA silencing of NOD1
decreased the activation of downstream targets, including RIP2
and NOS2, in HL-1 cells exposed to glucose and palmitate
(Figure 3B). Importantly, exposure of HL-1 cardiomyocytes
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separately to glucose or palmitate failed to induce changes in
NOD1 expression (results not shown). The addition of glucose
plus palmitate to HL-1 cells also promoted the activation of pro-
apoptotic pathways, increasing activated caspase-3 and decreas-
ing the anti-apoptotic protein X-IAP (Figure 3C). Significantly,
activation of apoptosis was prevented in cardiomyocytes silenced
for NOD1 expression (Figure 3C). Importantly, NOD1 silencing
did not affect pro-inflammatory and pro-apoptotic pathways un-
der basal conditions (results not shown). To determine whether
high glucose/fatty acid treatment up-regulated NOD1 at the tran-
scriptional level, we have treated HL-1 cells as before together
with a selective inhibitor of transcription (actinomycin D). Res-
ults revealed that the addition of actinomycin D prevented NOD1
up-regulation induced by the high glucose/fatty acids adminis-
tration (Figure 3D), demonstrating that the increase in NOD1
expression occurs at the level of transcription.
NOD1 is overexpressed in the myocardium of
diabetic patients
Having demonstrated the activation of NOD1 in diabetic mur-
ine myocardium, we next sought to identify whether a similar
situation occurred in human pathology. To this end, we have
measured NOD1 protein expression in myocardium samples of
left ventricle from T2DMH and NH. Table 1 gives the human
biochemical data from the patients. Representative immunohis-
tochemistry images of NOD1 expression in a sample from an
NH and T2DMH are shown in Figure 4. Transversal sections
were stained with H&E to distinguish the underlying histology
(Figures 4a and 4b). NOD1 expression was marked signific-
antly in both transversal (Figures 4c and 4d) and longitudinal
(Figures 4e and 4f) sections of T2DMH compared with NH.
Importantly, no background staining was observed when us-
ing only the secondary antibody (Supplementary Figure S6 at
http://www.clinsci.org/cs/127/cs1270665add.htm). In addition,
immunofluorescence analysis showed that NOD1 protein expres-
sion in T2DMH was increased significantly (1.9 +− 0.1 arbitrary
units in T2DMH compared with 1.1 +− 0.1 arbitrary units in NH;
P< 0.01; Supplementary Figure S7 at http://www.clinsci.org/cs/
127/cs1270665add.htm). Consistent with our in vitro experi-
ments, immunohistochemical analysis suggested NOD1 over-
expression in the cardiomyocyte population, defined as easily
identifiable rod-shaped cells in longitudinal sections (Figures 4e
and 4f, and Supplementary Figure S7). Furthermore, sections
of hearts from T2DMH showed increased staining for the pro-
inflammatory cytokine TNF-α (Figure 5A) together with a higher
percentage of cells stained positively for caspase-3, compared
with sections of hearts from NH (1.7 +− 0.2‰ of caspase-3-
positive cells in T2DMH compared with 0.0 +− 0.0‰ found in
NH; P< 0.01, Figure 5B).
DISCUSSION
In the present report, we have demonstrated that the myocardium
from mouse models of diabetes and human myocardium of pa-
tients with Type 2 diabetes overexpress the receptor of the innate
immune system NOD1. This up-regulation occurred in cardio-
myocytes and was associated with an increased apoptotic profile.
During their lifetime, humans are confronted frequently with
pathogens. To resolve an infectious process, the innate immune
system uses a complex signalling network to modulate the del-
icate balance between stimulation and inhibition of host immune
responses. Imbalances in the innate immunity system promote
chronic inflammatory and autoimmune processes that can po-
tentially participate in the onset of several pathologies including
diabetes [7,37]. In this context, it has been proposed that some
mediators of the innate immune response might contribute to
ongoing obesity-associated insulin resistance, indicating a con-
nection between innate immunity and metabolic regulation. Both
TLRs and NLRs, the most prominent mediators of the innate
immune system, participate in coronary heart disease, myocar-
dial infarction and diabetes [5,8,38–40]. NOD1, a member of the
NLR family, has been associated with the induction of chronic in-
flammatory disorders, such as atopic eczema and asthma [41,42].
These examples underscore the importance of this receptor in the
regulation of the immune response [43,44], including NF-κB ac-
tivation, cytokine production and induction of apoptosis [45,46].
At the vascular level, NOD proteins can mediate several inflam-
matory responses [16,17]. However, despite the marked progress
in understanding the role of NLR/NOD signalling in host de-
fence, their contribution to inflammatory cardiac disorders re-
mains poorly characterized [47].
Recent studies point to a direct relationship between NOD
proteins and diabetes. In this respect, some studies have reported
that NOD proteins participate in insulin resistance and inflammat-
ory responses in hepatocytes from diabetic mice [7]. Cross-talk
between diabetes-related inflammation and NOD1 activity ap-
pears to be a relevant physiopathological condition in some tar-
get tissues, such as the heart. In addition, other pro-inflammatory
mediators have been considered as a bridge between metabol-
ism and the immune system. This is the case with TLRs, which
are additional pattern-recognition receptors implicated in insulin
resistance. Accordingly, TLR4 has been proposed as an immune
receptor that can alter metabolism [9] and can recognize not only
exogenous but also endogenous ligands, for example modified
low-density lipoprotein (LDL) [38], an established cardiovascu-
lar risk factor for Type 2 diabetes linked to obesity.
In the present report, we have demonstrated that cardiac tissue
from mice with Type 2 diabetes expresses higher levels of NOD1,
together with increased production of pro-inflammatory cy-
tokines including TNF-α, IL-1β and IL-6. Supporting these find-
ings, other studies have described that NOD1 activation promotes
insulin resistance in adipocytes and hepatocytes [7,24,27,28].
Moreover, monocytes isolated from patients with Type 2 diabetes
have higher expression of NOD1 compared with normoglycaemic
individuals [25]. Furthermore, Schertzer et al. [7] have demon-
strated in a model of Type 2 diabetes induced by an HFD that the
absence of NOD protects against lipid accumulation and insulin
resistance. Collectively, these observations support the involve-
ment of NOD1 in metabolic disorders.
Regarding the mechanism responsible for activation of
NOD1 in the heart of db mice, a plausible explanation might be
that NOD1 is activated by fatty acids. This notion is supported by
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Figure 3 HL-1 cardiomyocytes incubated with high doses of glucose and palmitate promote NOD1 pathway activation
and apoptosis induction
(A) Representative immunostaining of NOD1 obtained in HL-1 cardiomyocytes incubated 48 h with vehicle (Veh.) or
with 50 mmol/l glucose plus 200 μmol/l palmitate (G + P); a negative control of each example is shown in the inset.
Mean fluorescence values +− S.E.M. in arbitrary units are inserted in the images. (B) Representative blots of NOD1,
phospho-RIP2/RIP2 and NOS2 obtained in HL-1 cells treated with Veh., G + P or G + P + siRNA of NOD1 (G + P + siRNA).
(C) Left panel shows representative blot of activated caspase-3 and X-IAP obtained in Veh., G + P and G + P + siRNA-treated
cells. (D) Representative blot of three different experiments representing NOD1 expression in HL-1 cells treated with Veh.,
G + P or G + P + 0.1 μg/ml actinomycin D (G + P + Ac). Means +− S.E.M. (n= 3–5) are expressed as a percentage compared
with wt mice (100 %). ∗P< 0.05, ∗∗P< 0.01 and ∗∗∗P< 0.001 compared with Veh.
our findings in cardiomyocytes treated with high concentrations
of glucose and palmitate. This environment leads to transcrip-
tional up-regulation of NOD1, together with activation of down-
stream signalling. Importantly, this activation was abrogated by
siRNA silencing of NOD1 (Figure 3). Indeed, Zhao et al. [48]
showed that increased lipid metabolites, associated with Type 2
diabetes, can be detected by NOD proteins, and, more recently,
Cuda et al. [28] described that the Glu266Lys polymorphism
in the NOD1 gene affects the relationship between nutritional
saturated fatty acid intake and insulin sensitivity.
Up-regulation of NOD1 oligomerization through its
nucleotide-binding domain results in activation of different path-
ways, of which the best characterized is NF-κB [23]. Our data
show that NF-κB is activated in cardiac tissue of db mice
(Figure 1). The sustained up-regulation of the NOD1/NF-κB
axis observed in the hearts of db mice correlates with NLR
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Figure 4 NOD1 is up-regulated in cardiac tissue from Type 2 diabetic patients
Representative H&E-stained slides of hearts from NH (a) and T2DMH (b) (×10). (c–e) Immunohistochemistry staining
demonstrating that NOD1 is overexpressed in both transversal (c, d, ×10; insert ×40) as well as longitudinal (e, f, ×40)
myocardial sections of hearts from T2DMH relative to NH. Bar = 100 μm.
activation in isolated cells. Thus, our results provide evidence
of functional activation of the classical NF-κB pathway, includ-
ing phosphorylation of IKK, and the expression of target genes
such as COX2 and NOS2. NF-κB activation induced by NOD1
is the result of an interaction between the caspase recruitment
domain (CARD) of NOD1 and the equivalent CARD of RIP2
[23], a kinase that specifically amplifies downstream signalling
from NOD proteins but not from other TLRs [49–51]. The pre-
cise function of this kinase is not fully elucidated, but studies
with genetic mouse models suggest that RIP2 activity is required
for an appropriate innate immune response promoted via NOD
receptors [52]. We have demonstrated that RIP2 is activated in
both the hearts and cardiomyocytes of db mice, corroborating
the pathway activation of this NLR in the cardiac milieu in our
models.
Apoptotic events have been implicated in the diabetic process
[53], although the precise mechanism(s) remain unknown. NLR
proteins harbour functions beyond those engaged with the innate
immune response, including the regulation of cell death [23,54].
Our previous work established that NOD1 activation induces ap-
optosis in the heart and in isolated cardiomyocytes [22]. In the
present study, we have shown that both cardiac tissue and isolated
cardiomyocytes from db mice display a prominent pro-apoptotic
profile, exhibiting a greater degree of DNA fragmentation com-
pared with wt mice. Furthermore, pro-apoptotic mediators, such
as activated caspase-3 and BAX, were increased, whereas cell
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Figure 5 TNF-α and caspase-3 are up-regulated in myocardium of Type 2 diabetic individuals
(A) Myocardial longitudinal sections of hearts from NH and T2DMH were stained with an antibody to TNF-α (×40); images
from transversal sections are inserted in each photomicrograph. (B) Myocardial sections from NH and T2DMH were stained
with an antibody to caspase-3 (×40). Caspase-3 staining in both transversal (b) and longitudinal (d) sections of T2DMH
shows a high expression of this mediator compared with NH (a, c).
viability and the anti-apoptotic protein X-IAP were reduced in
cardiac tissue and cardiomyocytes from db mice. These results
were validated in the HL-1 cardiomyocyte cell line. HL-1 cells
treated with high concentrations of glucose plus palmitate dis-
played a pro-apoptotic profile, which was lost upon NOD1 silen-
cing. This relationship between NOD1 activation and caspase-
dependent apoptosis is well established by several groups, in-
cluding ours [20,21,23]. Indeed, the CARD of NLR proteins can
interact with the homologous CARD of caspases, triggering an
induction of apoptosis. Reinforcing these results, treatment of db
mice with a selective agonist of NOD1 induces both NF-κB and
apoptosis pathways (Supplementary Figure S4), demonstrating
the sensitivity of the db model to apoptosis induction by specific
NOD1 stimulation.
In an attempt to connect our murine data to human patho-
logy, we have analysed NOD1 protein in cardiac tissue from
T2DMH and NH. Immunohistochemistry and immunofluores-
cence demonstrated that T2DMH samples exhibited greater
NOD1 expression than NH; this increase was detected notably
in cardiomyocytes. Furthermore, levels of the pro-inflammatory
cytokine TNF-α were also enhanced in T2DMH compared with
NH. Finally, consistent with our results, in the db mice model, the
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T2DMH group also showed increased levels of the pro-apoptotic
mediator caspase-3. To the best of our knowledge, this is the
first demonstration of NLR activity in the human heart. In this
context, other mediators of the innate immune system, such as
TLR4, are increased in human failing myocardium [55], support-
ing the idea of cross-talk between innate immune mediators and
cardiovascular disease.
During the last decade, the role of the inflammatory response
during the onset of diabetes and potential inhibition of inflam-
matory mediators as alternative or complementary strategies for
the management of this disease has received increased attention
[56]. Moreover, some evidence supports the idea that chronic
inflammation can be a consequence of an inability to shut down
the inflammatory response. This is supported by studies demon-
strating spontaneous inflammatory events in patients and animals
with particular mutated or disrupted genes. Importantly, some of
these genes encode proteins which are known to be highly pro-
inflammatory, such as the transcription factor NF-κB, emphas-
izing the complexity of immune regulation. Although further
studies will be required to address the specific role of NOD1 in
diabetic cardiomyopathy, the present report uncovers a new im-
mune player in the heightened inflammatory response in both
human and murine diabetic diseases.
CLINICAL PERSPECTIVES
 NOD1 activity is associated with many pro-inflammatory con-
ditions; however, little is known regarding its contribution to
cardiovascular pathologies.
 Our data in animal models and in patients provide strong
evidence for an association between Type 2 diabetes and over-
expression of NOD1 in cardiac tissue. In addition, we have
provided functional evidence, which links the up-regulation
of NOD1 to its activation and contribution to chronic low-
grade inflammation in the heart.
 Inhibitors of NOD1 are potential therapeutics for diseases
with an inflammatory component. The present study identi-
fies relevant targets to assess their potential efficacy in the
management of cardiac dysfunction in Type 2 diabetes. Un-
ravelling the therapeutic value of pharmacological inhibitors
of NOD1 might provide additional tools for the assessment of
cardiac dysfunction associated with up-regulation of NOD1.
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MATERIALS AND METHODS
HFD feeding
For the high-fat diet (HFD) exeriments, 4-week-old C57BL/6J
male mice (wt) weighing 16–18 g were housed under a 12/12-h
light–dark cycle in a temperature-controlled room (22 ◦C), with
standard food and water available ad libitum. Mice were divided
into two groups of similar average body weight, housed four
per cage and assigned to either a control regular chow diet or a
42 % HFD (TD. 88137, Harlan Laboratories). Body weight and
food intake were monitored once per week. After 12 weeks of
treatment, mice were killed, and heart tissues were snap-frozen
in liquid nitrogen and stored at − 80 ◦C.
Glucose and insulin determination
Plasma glucose was measured in a Reflotron plus (Roche). Insulin
was quantified with the Rat/Mouse Insulin 96-Well Plate Assay
Kit.
Immunofluorescence staining
HL-1 cells were seeded on to sterile eight-well Chamber Slides
(Falcon) and fixed with 2 % paraformaldehyde for 10 min. Cells
were permeabilized in ice-cold methanol and incubated with 3 %
BSA for 30 min. After incubation with a rabbit antibody against
glucose transporter 4 (GLUT-4) (1:500 dilution; Abcam) at 4 ◦C
overnight, cells were washed with PBS followed by incubation
with Alexa Fluor® 488-conjugated goat anti-rabbit secondary an-
tibody (1:500 dilution; Molecular Probes) for 1 h at room temper-
ature. Coverslips were mounted in Prolong Gold antifade reagent
(Molecular Probes) and examined using a Leica TCS SP5 spec-
tral confocal microscope. Alexa Fluor® fluorescence was excited
using the 488 nm line of an argon laser and emission collected
through a band-pass filter (505–530 nm). DAPI fluorescence was
excited using a mercury lamp (band-pass 365/12) and emissions
1These authors contributed equally to the study.
Correspondence: Dr Mar´ıa Ferna´ndez-Velasco (email mvelasco@iib.uam.es or maria.fernandez@idipaz.es) or Professor Lisardo Bosca´ (email lbosca@iib.uam.es).
collected through a band-pass filter (480–520 nm). Fluorescence
intensity measurements were performed using ImageJ software
(NIH).
Immunohistochemistry of human samples
Samples were deparaffinized and then blocked by incubation for
60 min at room temperature with TBS, at pH 7.6, containing
10 % goat serum and 1.5 % BSA. Sections were then incubated
overnight at 4 ◦C with an anti-NOD1 antibody followed by three
5-min washes with TBS. Bound primary antibody was detected
by incubation for 45 min with biotinylated horse anti-goat sec-
ondary antibody (1:50 dilution; Vector Laboratories), followed
by three 5-min washes with TBS and then incubation for 30 min
with streptavidin conjugated to Alexa Fluor® 488 (1:1000 dilu-
tion; Molecular Probes). Slides were washed again three times in
TBS, rinsed once briefly in water and mounted under a coverslip
with VectaShield mounting medium with DAPI (Vector Laborat-
ories). Samples were visualized by epifluorescence microscopy.
Epifluorescence microscopy was performed on a Leica AF6000
by using a ×20 dry objective lens. Emission/excitation filters
for DAPI and Alexa Fluor® 488 were used. A sample with no
primary antibody was always included to control for background
generated by the secondary antibody.
Quantification of lipid incorporation by HL-1 cells
Accumulation of lipid by HL-1 cells was determined using the
lipophilic Nile Red fluorescent dye. Cells were incubated for
48 h with 50 mmol/l glucose and 200 μmol/l palmitic acid. HL-1
cells were trypsinized and centrifuged for 5 min at 200 g at 4 ◦C.
Cell pellets were re-suspended and fixed with 2 % paraformal-
dehyde at 4 ◦C. For flow cytometry, cells were sedimented as
described above, re-suspended in PBS with a final Nile Red con-
centration of 0.4 μg/ml (30 min). Fluorescence emission was
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Figure S1 Body weight and plasma levels of glucose and insulin in db mice
Body weight (A), glucose (B) and insulin (C) plasma levels obtained in db mice. Data are expressed as means +− S.E.M.
of the percentage of the corresponding wt mice (100 %). ∗∗∗P< 0.001 compared with their corresponding wt mice.
Figure S2 NOD1 protein expression, body weight, and plasma levels of glucose and insulin obtained in HFD-treated mice
Representative immunoblot and average data of NOD1/GAPDH expression obtained in cardiac tissue of wt mice and
HFD-fed mice (A). Body weight (B), and glucose (C) and insulin (D) plasma levels obtained in HFD-fed mice for 12 weeks.
Data are expressed as means +− S.E.M. of the percentage of the corresponding wt mice (100 %). ∗P< 0.05 and ∗∗∗P<
0.001 compared with the corresponding wt.
detected between 564 nm and 604 nm with band-pass filter using
FACScan flow cytometer (FC-500 Becton Dickinson). Data ana-
lysis was presented using forward scatter (FSC) compared with
fluorescence, where the percentage of lipid accumulation was
calculated on the basis of the cells stained with high fluorescence
values.
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Figure S3 Staurosporine induces apoptosis in isolated native cardiomyocytes
Staurosporine (100 ng/ml) decreases cell viability (left panel) and increases the TUNEL-positive nuclei (right panel) in
cardiomyocytes from wt and db mice. Data are expressed as means +− S.E.M. of the percentage of the corresponding wt
mice (100 %); n= 3–5 animals per condition. ∗P< 0.05 compared with wt mice; &P< 0.05 compared with db mice.
Figure S4 Selective stimulation of NOD1 induces NF-κB and ap-
optotic pathway activation
Animals received intraperitoneal iEDAP (5 μg/g of body weight; iE), a
selective agonist of NOD1, or vehicle. After 2 weeks of treatment up-reg-
ulation of phospho-RIP2/RIP2, phospho-IKK/IKK, phospho-IκBα/IκBα,
NOS2 and COX2 proteins were observed in hearts from wt and db mice
(A). IE administration also promoted an increase in the number of TUN-
EL-positive nuclei (B), caspase-3 and BAX levels, and a decrease in
X-IAP protein levels (C). Data are expressed as means +− S.E.M. com-
pared with the corresponding wt mice (100 %). ∗P< 0.05 compared with
wt mice; &P< 0.05 compared with db mice; n= 4–6 animals.
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Figure S5 HL-1 cells incubated with palmitate and glucose reveal changes in insulin signalling and lipid accumulation
(A) Nile Red fluorescence staining demonstrates lipid incorporation in HL-1 cells incubated for 48 h with 50 mmol/l
glucose and 200 μmol/l palmitate. Left panel shows an example obtained in vehicle-treated cells (Veh.) and the right
panel illustrates an example obtained in cells incubated with glucose and palmitate (G + P). The mean values have
been added to the Figure (n= 3). (B) Representative immunoblots of phospho-Akt/Akt, phospho-InsulinR/InsulinR (insulin
receptor) and GAPDH from cells treated for 48 h with Veh. or with 50 mmol/l glucose and 200 μmol/l palmitate (G + P)
and treated with insulin (100 nmol/l) for 5 min prior to collection. Insulin failed to phosphorylate both the Akt and InsulinR
in G + P-treated cells. Representative immunoblots from three different experiments. (C) Immunofluorescence of GLUT-4 in
HL-1 cells incubated with 50 mmol/l glucose and 200 μmol/l palmitate (G + P) for 48 h and treated with insulin (100
nmol/l) for 5 min. Vehicle-treated cells (Veh.) incubated with insulin for 5 min showed a prominent GLUT-4 transmembrane
localization (arrows) compared with vehicle-treated cells under basal conditions (left panel). G + P-treated cells incubated
with insulin did not show GLUT-4 transmembrane localization, suggesting that G + P-treatment induces an impairment in
insulin-induced glucose transporter localization.
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Figure S6 Negative control for NOD1 immunohistochemistry staining
Longitudinal heart section incubated with a mouse IgG instead of the primary antibody for NOD1. Scale = 100 μm.
Figure S7 NOD1 is up-regulated in the myocardium of T2DMH
Myocardial sections of NH and T2DMH were stained with a NOD1 antibody (×40). Bright-field phase-contrast images are
shown in panels (a) and (b). NOD1 staining revealed high expression of this NLR in T2DMH compared with NH (c, d).
Negative controls obtained for each sample are shown in the insets.
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Involvement of monocytes/macrophages as key factors in the
development and progression of cardiovascular diseases
Mar´ıa FERNA´NDEZ-VELASCO*1, Silvia GONZA´LEZ-RAMOS† and Lisardo BOSCA´†1
*Instituto de Investigacio´n Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
†Instituto de Investigaciones Biome´dicas Alberto Sols, CSIC-UAM, Arturo Duperier 4, 28029 Madrid, Spain
Emerging evidence points to the involvement of specialized cells
of the immune system as key drivers in the pathophysiology of
cardiovascular diseases. Monocytes are an essential cell compon-
ent of the innate immune system that rapidly mobilize from the
bone marrow to wounded tissues where they differentiate into
macrophages or dendritic cells and trigger an immune response.
In the healthy heart a limited, but near-constant, number of
resident macrophages have been detected; however, this number
significantly increases during cardiac damage. Shortly after initial
cardiac injury, e.g. myocardial infarction, a large number of
macrophages harbouring a pro-inflammatory profile (M1) are
rapidly recruited to the cardiac tissue, where they contribute to
cardiac remodelling. After this initial period, resolution takes
place in the wound, and the infiltrated macrophages display a
predominant deactivation/pro-resolution profile (M2), promoting
cardiac repair by mediating pro-fibrotic responses. In the present
review we focus on the role of the immune cells, particularly in the
monocyte/macrophage population, in the progression of the major
cardiac pathologies myocardial infarction and atherosclerosis.
Key words: cardiovascular disease, fibrosis, inflammation,
monocyte, macrophage.
INTRODUCTION
CVDs (cardiovascular diseases) are the leading cause of death
in the developed world. Despite marked progress in the
understanding of CVD, the underlying mechanisms involved
in many of these pathologies have not been completely
elucidated [1,2]. Most CVDs share a common low-grade chronic
inflammatory state. Overwhelming evidence supports the view
that specialized cells of the immune system, including Mo
(monocytes)/Mϕ (macrophages), contribute to CVD through cell–
cell interactions by releasing pro-inflammatory and chemotactic
factors and proteases that promote cell recruitment, cell
apoptosis, angiogenesis and extracellular matrix remodelling
[3–8]. Accordingly, clinical signs of inflammation in heart failure
patients, such as elevated cytokine levels or enhanced C-reactive
protein, are associated with detrimental ventricular remodelling
[9].
Mo/Mϕ constitute an important cell population of the innate
immune system and are normally produced from haematopoietic
stem cell precursors in the bone marrow. Specific changes in
the number of blood Mo can be used as CVD markers. Indeed,
a positive correlation between high blood levels of Mo has been
reported in hypercholesterolaemic individuals with coronary heart
disease [10]. In response to inflammatory signals, Mo can rapidly
traffic from the blood to injured tissues and differentiate into Mϕ
or dendritic cells, triggering an immune response. More recently,
studies in murine models of MI (myocardial infarction) have
shown that Mo recruitment is not only derived from bone marrow
precursors, but also by extramedullary monocytopoiesis in the
spleen [11–14].
Resident Mϕ in the healthy heart account for approximately
1–5% of the cell population; however, their numbers
rise significantly during cardiac damage [13,15–17]. Under
physiological conditions, tissue Mϕ express genes resembling
an anti-inflammatory/deactivation profile (M2) [18]. After
cardiac injury, e.g. MI, large numbers of Mϕ harbouring a
robust pro-inflammatory profile (M1) are rapidly recruited by
the cardiac tissue early in the process. These inflammatory
Mϕ contribute to cardiac remodelling by accelerating cardiac
apoptotic events. After injury, the resolution phase of the
inflammatory response takes place in the heart wound, and
the infiltrated Mϕ predominantly display an M2 profile.
Interestingly, cardiac fibrosis is a pathological process closely
related to the inflammatory response during CVD [19] and
Mo/Mϕ participate in the initiation, progression and repair of
cardiac fibrosis [20]. Accordingly, Mϕ phagocytosis can act as
pro- or anti-fibrotic, depending on the microenvironment, thereby
modulating extracellular matrix deposition and promoting cardiac
remodelling [21,22]. The present review focuses on the role of
these specialized immune cells in some CVDs such as MI and
atherosclerosis.
ONTOGENY AND FATE OF Mo/Mϕ
Mo are innate immune cells derived from the myeloid lineage in
the bone marrow [23]; however, under certain conditions, such as
inflammation, extramedullary monocytopoiesis has been reported
[12,24]. Consequently, some authors have suggested that resident
Mo/Mϕ can also be recruited at inflammatory sites, where they
Abbreviations: ACE, angiotensin-converting enzyme; CCR2, CC chemokine receptor 2; CVD, cardiovascular disease; CX3CR, CX3C chemokine
receptor; ECM, extracellular matrix; FGF, fibroblast growth factor; IL, interleukin; LDL, low-density lipoprotein; Ly-6C, lymphocyte antigen 6C; M1,
pro-inflammatory macrophage; M2, anti-inflammatory/deactivation macrophage; MCP-1, monocyte chemoattractant protein-1; Mϕ, macrophage(s); MI,
myocardial infarction; MMP, matrix metalloproteinase; Mo, monocyte(s); oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; TGF-β,
transforming growth factor β; TLR, Toll-like receptor; TNF-α, tumour necrosis factor α; VEGFR2, vascular endothelial growth factor receptor 2.
1 Correspondence may be addressed to either of these authors (email mvelasco@iib.uam.es/maria.fernandez@idipaz.es or lbosca@iib.uam.es).
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Table 1 Major markers of monocyte subsets in both mice and humans
Mouse monocyte subsets Distinctive markers Human monocyte subsets Distinctive markers
Ly-6Chigh CCR2high, CX3CR1low, CD62L+ and Gr1 CD14high/CD16low CCR1, CCR2, CXCR1, CXCR2, CX3CR1, CD36, CD38, CD62L, CD64 and CD99
Ly-6Clow CCR2low, CX3CR1high, CD62L− and CD11c CD14low/CD16+ CX3CR1, CD32, CD86 and MHC II
Ly-6Cint CCR2high, CCR7, CCR8 and Gr1 CD14high/CD16+ CCR2, CX3CR, CXR4, CD105, HLA-DR, ACE and VEGFR2
differentiate into activated Mϕ and contribute to wound healing
[25,26]. Mo from the bone marrow enter the blood via CCR2 (CC
chemokine receptor 2) motifs [27], arriving at different tissues
where they differentiate into Mϕ. In mice, Mo are typically
classified according to the expression of Ly-6C (lymphocyte
antigen 6C). Ly-6Chigh Mo are CCR2high, CX3CR1low (where
CX3CR is CX3C chemokine receptor), CD62L+ and Gr1+ ,
whereas Ly-6Clow Mo are CCR2low, CX3CR1high and CD62L−
[26,28]. In addition, intermediate Ly-6C Mo (Ly-6Cint, CCR2high,
Gr1+ ) have also been described to play an important role in
the inflammatory response [29–31]. Ly-6Chigh Mo were originally
referred to as inflammatory or classical Mo/Mϕ, accumulating in
the inflammatory focus, where they rapidly give rise to polarized
Mϕ. Indeed, during inflammation, a significant increase in Ly-
6Chigh cells occurs, contributing to monocytic events [13]. Ly-
6Clow Mo, named resident or non-classical Mo, have been reported
to accumulate in tissues under homoeostatic conditions [32].
The percentages of Ly-6Chigh and Ly-6Clow Mo are similar under
healthy conditions, whereas upon cardiac injury the number of
Ly-6Chigh Mo are significantly augmented (see below) [7,13].
Although murine and human Mo share some common properties,
many differences have been recently established related to
function and phenotype in both species, therefore comparisons
between them should be cautiously considered. Human Mo
are classified according to their CD14/CD16 expression level
[33]. Similar to murine Mo, at least two main subsets have
been characterized to date. In healthy individuals, the majority
of human Mo display a CD14high/CD16low (CD14+ + /CD16− )
profile, rather than CD14low/CD16+ (CD14+ /CD16+ or CD14dim)
which represents only 5–15% of the Mo population. Recently,
a third subset of Mo, CD14high/CD16+ (CD14+ + /CD16+ ),
has been identified in human blood [34]. This subtype is
reminiscent of the Ly-6Chigh Mo population in mice. With
regards to the expression of adhesion molecules and chemokine
receptors of each subtype, CD14high/CD16low Mo express CCR2,
CX3CR1, CD62L and CD64, and are found to be significantly
increased in an inflammatory context (sharing many features
of murine Ly-6Chigh cells). CD14dim Mo lack CCR2 and
express high levels of CX3CR1, CD32 and histocompatibility
complex II. CD14dim are closely associated with Ly-6Clow
Mo [35,36]. The intermediate CD14high/CD16+ Mo express
higher levels of CX3CR, CXR4 and CCR2. This subset also
expresses ACE (angiotensin-converting enzyme) and VEGFR2
(vascular endothelial growth factor receptor 2), which are
intimately involved in angiogenesis and cardiac remodelling
[37]. CD14high/CD16+ Mo are also the main producers of ROS
(reactive oxygen species). Functionally, CD14dim are considered
as sentinels of the vasculature, whereas CD14high/CD16+ and
CD14high/CD16low Mo contribute to inflammatory processes. Both
CD14high/CD16+ and CD14high/CD16low Mo respond to TLR2/4
(Toll-like receptor 2/4) ligands, whereas CD14dim cells respond to
TLR7/8 stimuli [35]. A summary of the comparison between the
markers of human and murine Mϕ is shown in Table 1.
Following the ontogeny lineage, Mϕ acquire their main
biological functions upon tissue accumulation. Nevertheless, a
recent sophisticated view, based on complementary experimental
evidence, points to the possibility of a non-haemopoietic origin
of some tissue Mϕ subsets (i.e. Langerhans cells in the skin or
proliferation of recruited Mϕ in the atheroma lesion [29,38]).
Therefore this field remains open to new questions concerning
the possible origin of these cells from local precursors that
were seeded from the yolk sac before haemopoiesis was
completed [39–41]. Indeed, Mo/Mϕ constitute a heterogeneous
cell population. Acknowledging the origin of Mϕ, two lineages
of Mϕ have been recently defined in mice [42]: F4/80low CD11bhigh
Mϕ derived from bone marrow, and F4/80high Mϕ derived from
the yolk sac. The specific functions of both populations are not yet
completely understood. With regard to the classification of Mϕ,
many possibilities have been established, but the most common
refers to the M1/M2 classification. Bone marrow precursors can be
differentiated into Mϕ in vitro in a variety of ways; those generated
in the presence of GM-CSF (granulocyte/Mϕ colony-stimulating
factor), lipopolysaccharide or IFN-γ (interferon γ ) are called M1
or classically activated Mϕ. M1 Mϕ produce high levels of pro-
inflammatory mediators such as TNF-α (tumour necrosis factor
α), IL (interleukin)-1β, IL-6, IL-12 and inducible nitric oxide
synthase. Conversely, precursors maintained in the presence of
IL-4, IL-10 or IL-13 generate M2 or alternatively activated Mϕ,
and produce anti-inflammatory products such as arginase-1, IL-10
and CD206, and display a pro-resolution profile [29,43,44].
Under homoeostatic conditions the majority of organs, includ-
ing the heart, contain a small population of Mϕ; however, when
a pro-inflammatory injury occurs, increased numbers of blood
Ly-6Chigh Mo are extravasated into the tissue and differentiate
into M1 Mϕ. In the following resolution phase, M1 Mϕ
are replaced by M2 Mϕ. Accordingly, a conversion of M1 into
M2 has been proposed [45–47]. Nonetheless, in response to
inflammatory damage Ly-6Clow, Mo can also extravasate into the
heart where they differentiate into M2 Mϕ, thus promoting cardiac
repair and remodelling [48]. Alternatively, it has been suggested
that M2 Mϕ may also derive from Ly-6Chigh Mo, that under a pro-
resolution environment can differentiate into M2 subsets [49];
however, this hypothesis needs further confirmation.
ATHEROSCLEROSIS AND INFLAMMATORY MYELOID CELLS
Despite the exceptional advances in medicine arising during the
last half century, CVD remains the most common cause of death in
industrialized nations [2]. Atherosclerosis underlies the majority
of CVD and its slow progression into a chronic disorder may cause
thrombotic events [50]. Atherosclerosis affects the structure and
function of arterial blood vessels, and results from the deposition
of fatty material such as cholesterol and triacylglycerols
into the lumen of arteries. Although atherosclerosis is a
complex disease, important evidence suggests that inflammatory
mediators may be key factors in disease progression [51–54].
In the initial stages of atherogenesis, activation of endothelium
induces an increase in the expression of adhesion molecules,
reducing barrier function and promoting leucocyte and Mo
recruitment in the arterial wall [55,56]. In this scenario, Mo
recruited to the endothelium of vessels quickly differentiate
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Figure 1 Initial phase of atherosclerosis
Plasma LDL is converted into oxLDL by various cellular and biochemical mediators in the
subendothelial space. OxLDL promote, via endothelial cells, the differentiation of Mo into
Mϕ that take-up the oxLDL, converting them into foam cells. Activated Mϕ express a variety of
cytokines which stimulate endothelial cells to express adhesion proteins, supporting the binding
of additional blood Mo to the endothelium and their recruitment into the intima. Interactions
between Mϕ and T-cells result in a broad range of cellular and humoral responses, establishing
a chronic inflammatory process. Th1/2, T-helper cell type 1/2. An animation is available online
at http://www.biochemj.org/bj/458/0187/bj4580187add.htm.
into Mϕ that phagocytize modified lipids [oxLDL (oxidized
low-density lipoprotein)] accumulated inside of arteries, leading
to foam cell formation and contributing to the atheroma core
development [6] (Figure 1). Furthermore, these Mϕ amplify the
inflammatory response through the release of pro-inflammatory
cytokines and growth factors, promoting a local Mϕ proliferation
inside the atheroma lesion, hence offering new and previously
unexpected therapeutic approaches [38,57]. This inflammatory
amplification attracts additional immune cells into the vessel’s
intima, promoting the formation of advanced atherosclerotic
plaques and increasing profibrotic and necrotic events (Figure 2
and see the animation online at http://www.biochemj.org/bj/
458/0187/bj4580187add.htm). At the end of the process, the
subendothelial prothrombotic material is exposed and the
dissolution of the fibrous cap occurs. Thereafter, the coagulation
cascade is activated, inducing thrombus formation and promoting
vascular occlusion [58] (Figure 3). This process is aggravated
when recurrent pro-inflammatory events occur, due to the capacity
of Mϕ to promote remodelling and destabilization of atheroma.
Many studies suggest that Mo are key factors in the initiation
and progression of atherosclerotic lesions. Indeed, a rise in
infiltration of Ly-6Chigh cells in the atherosclerotic core mainly
via CCR2 and CX3R1 has been reported by different groups
[13,59,60]. When the inflammatory input persists, Ly-6Chigh Mo
differentiate into M1 Mϕ by expressing inflammatory mediators
and contribute to oxidative stress [24]. In contrast, Ly-6Clow
cell infiltration is less frequent in atherosclerotic lesions [61].
Interestingly, Mo recruited to the atherosclerotic lesion not
only derive from the bone marrow, but also from the splenic
reservoir, and as previously mentioned, from local proliferation
[24,38]. Experimental data obtained in Apo-E-deficient mice
(hypercholesterolaemic mice) demonstrated that these mice fed
with a high-fat diet display an increase in the number of blood
Ly-6Chigh Mo and their adhesion to the damaged endothelium was
augmented, thus increasing their differentiation to detrimental
Mϕ [13,59,62]. The treatment of these mice with statins reduces
Figure 2 Atheroma progression phase
Cytokines released from Mϕ and foam cells stimulate not only the VSMCs (vascular smooth
muscle cells) to migrate into the intima, proliferate and secrete pro-fibrotic agents, but also the
endothelial cells, to contribute to the resulting fibrous cap formation. An animation is available
online at http://www.biochemj.org/bj/458/0187/bj4580187add.htm.
Figure 3 Plaque rupture and thrombosis
Necrosis of Mϕ and smooth muscle cell-derived foam cells leads to the formation of a
necrotic core and accumulation of extracellular cholesterol. Mϕ secrete MMPs and promote
neovascularization, contributing to weakening of the fibrous plaque. Plaque rupture exposes
blood components to tissue factor, initiates coagulation, the recruitment of platelets and the
formation of a thrombus, which narrows the arterial passage, restricting blood flow.
the cholesterol blood levels, and decreases the number of Ly-
6Chigh Mo that diminish the lesion formation [13]. More recently,
a study has reported that siRNA knockdown of CCR2 blocks Mo
recruitment in atherosclerotic plaques, and reduces the infarct size
after coronary occlusion [11].
In humans, a positive correlation between high blood levels of
CD14dim Mo and an increase in cholesterol and triacylglycerol
levels have been reported in hypercholesterolaemic individuals
with coronary heart disease [10]. Moreover, the percentage of
CD16+ Mo is usually high in patients with coronary artery
disease [63]. Mϕ also play an important role in the progression of
atherogenic lesions. On one hand, a rise of Mϕ infiltration occurs
in vascular lesions, increases the modified LDL (low-density
lipoprotein) phagocytosis and raises the secretion of cytokines,
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Figure 4 Diagram of the main features associated with MI disease
MI results from an injury. During the first minutes after MI, a significant accumulation of immune
cells occurs in the healing infarct. Mo/Mϕ are the main cell population that infiltrate into
the MI area. First, pro-inflammatory Mϕ (M1) dominate the infarcted region; in the second
phase, M1 Mϕ are replaced by a significant number of reduced pro-inflammatory myeloid cells
(M2) that contribute to resolution. During the first phase of MI, important pro-inflammatory
mediators and proteases are released in the cardiac wound. In the rebuilding phase, M2 cells
release pro-angiogenic and profibrotic mediators that participate in wound repair, and new
vessels and fibrotic tissue are formed. EF, ejection fraction; LV, left ventricle.
chemokines and ROS that promote tissue injury. Furthermore,
Mϕ induce plaque destabilization and rupture, reinforcing their
harmful role [64]. Nevertheless, beneficial roles have been
reported for Mϕ in atherosclerotic disease and some authors
suggest that Mϕ can participate in the repair processes that rescue
the physiological tissue homoeostasis [65].
ROLE OF Mo/Mϕ IN MI DAMAGE
MI is one of the most common ischaemic cardiac diseases and
constitutes a major proportion of the CVD rates. In most cases, MI
results from an atherosclerotic injury, as rupture of the atheroma
plaque promotes thrombus formation and impedes normal heart
oxygenation. Consequently, cardiomyocyte necrosis occurs very
quickly in the left ventricle (less than 1 h). MI takes place in
a chronic inflammatory milieu with highly active haemopoietic
and immune cells. During the first minutes after MI, a significant
accumulation of leucocytes occurs in the healing infarct [66,67].
Initially, there is a high proportion of neutrophils and Mo in
the infarcted region, whereas lymphocytes, dendritic cells and
mast cells arrive at the wound in lower proportions. Mo/Mϕ
are the main cell population that infiltrate into the infarcted
area. Two phases of infiltration are well defined after MI: first,
Ly-6Chigh Mo and corresponding pro-inflammatory Mϕ (M1)
dominate the infarcted region and are recruited in many cases
via MCP-1 (Mo chemoattractant protein-1) activity [68]; in the
second phase (approximately 4–7 days after MI), Ly-6Chigh Mo
are replaced by myeloid cells (Ly-6Cint/low Mo/M2-Mϕ) that are
less pro-inflammatory and contribute to resolution (Figure 4).
Significantly, a similar turnover of Mo/Mϕ (M1 to M2) subsets
are detected in blood from both murine models of MI and patients
with acute MI [15,69].
Predictably, compared with murine models, less information is
available on Mo and MI in humans. Although no data is available
from cardiac tissue, some authors describe that CD14high/CD16low
Mo are significantly increased in patients’ blood on day 3
after MI, whereas at 5 days after infarct CD14high/CD16+ cells
appear to be the main Mo population found [69]. This pattern
is similar to that observed in murine MI models [15]. Moreover,
MI patients with high numbers of pro-inflammatory circulating
Mo showed a significant cardiac contraction depression, and
their prognosis worsened [69]. Possibly, these pro-inflammatory
mediators aggravate the healing process after MI. More recently,
Tapp et al. [70] have also differentiated intermediate and non-
classical Mo in patients suffering MI. During the first phase of
MI, important pro-inflammatory mediators such as TNF-α and
proteases, derived from Ly-6Chigh/M1 activation, are released in
the cardiac wound. Thus activated Mϕ contribute to the removal
of debris in the infarcted region which is replaced by granulation
tissue and scar formation. In the rebuilding phase, Ly-6Cint/low
M2 cells release pro-angiogenic and pro-fibrotic mediators (i.e.
endothelial and transforming growth factors) that participate
in wound repair [15]. Finally, in order to restore the cardiac
damage, non-leucocyte populations such as endothelial cells and
fibroblasts/myofibroblasts also participate in the reconstruction of
the healing infarct; in many cases new vessels and fibrotic tissue
are formed [71,72].
Recent studies suggest a role for Mϕ in the regulation of red
blood cell generation and also in the close relationship with
pluripotent progenitor cells [73–75]. An interesting question
has arisen with regard to how Mo/Mϕ participate in tissue
regeneration after MI. Indeed, Mo can differentiate into
endothelial, epithelial or other types of cells under specific
culture conditions. An attractive hypothesis suggests that Mϕ can
interact with cells that bear regenerative capacities, contributing to
myocardium regeneration. Some studies report an enhancement
of blood and spleen haemopoietic progenitors and an increased
activity of bone marrow after MI [76–78]; however, their function
is not yet fully understood.
CONTRIBUTION OF Mo/Mϕ TO CARDIAC FIBROSIS DEVELOPMENT
Cardiac fibrosis is a common constituent of most cardiac
pathologies and represents the outcome of nearly all types of
cardiac injury [19]. It may appear in response to two distinct
stimuli: cardiomyocyte death as in MI; or, after different insults
(pressure overload, metabolic and toxic disturbances, brief
ischaemic events, etc.) that do not lead to cardiomyocyte loss.
Although in the first case the restorative response derives from the
formation of a collagen-based scar, in the second case it arises as
an adaptive response to maintain the pressure-generating ability of
the heart that may finally evolve into a state of replacement fibrosis
[79]. Fibrillar collagen that accumulates in the ECM (extracellular
matrix) remodelling process is a common consequence of these
pathophysiological conditions. This ‘increase’ in the collagen
content relative to basal levels is the classical histopathological
finding that the general term ‘fibrosis’ refers to.
Since Virchow’s work in the 19th Century, it has been
known that fibroblasts are the principal cell type responsible
for the imbalance of ECM composition in cardiac fibrosis [80].
As will be explained below, changes in fibroblast phenotype,
defined as changes in cell marker expression and function, occur
in a dynamic fashion [81]. The healing response following
MI encompasses inflammatory, proliferative (granulation) and
maturation phases. During the initial phase, activated Mϕ
and inflammatory cells produce a wide range of cytokines
and growth factors (fibrogenic mediators) including TGF-β
(transforming growth factor β), PDGF (platelet-derived growth
factor), FGF (fibroblast growth factor), TNF-α, CTGF (connective
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tissue growth factor) and MCP-1, to stimulate proliferation and
phenotypic differentiation of fibroblasts into myofibroblasts (α-
smooth muscle actin-positive cells). In the granulation phase,
myofibroblasts infiltrate the infarct area to contribute to injured
ventricle repair via sequential matrix degradation by ECM-
degrading MMPs (matrix metalloproteinases) and resynthesis of
ECM proteins. Post-MI remodelling includes both infarcted and
non-infarcted areas of the heart and causes enhanced interstitial
fibrosis in the remaining non-infarcted area [82].
Paying particular attention to the role of the Mo/Mϕ
inflammatory cells in cardiac fibrosis, the effort to highlight the
role that TGF-β plays through its effects on the inflammatory
and restorative response in the infarcted heart is of paramount
relevance. Experimental studies suggest that TGF-β may be
the ‘switcher’ that mediates the transition from inflammation to
scar formation following MI. Although TGF-β signalling can
activate peripheral blood Mo (increasing cytokine synthesis and
enhancing chemotaxis), it may deactivate Mϕ (chemokine down-
regulation and suppression of cytokine synthesis) and promote
myofibroblast transdifferentiation and ECM preservation [83–85].
Thus strategies directed to impair Mo infiltration have been
developed in an attempt to reduce fibrosis. In this respect, the
use of anti-MCP-1 gene therapy prevents Mϕ accumulation
and attenuates perivascular and interstitial fibrosis in MI [86].
Therefore Mo/Mϕ not only play important roles in initiation and
progression of fibrotic responses, but may also mediate resolution
of fibrosis [20]. Through their phagocytic properties, Mϕ can
exert pro-fibrotic and anti-fibrotic actions, removing dead cells
(thus facilitating growth of restorative fibroblasts) and clearing
apoptotic myofibroblasts and cellular and ECM debris (thus
eliminating key pro-fibrotic stimuli) [87].
The exact role of the Mϕ in scar healing has not been
fully clarified. Mϕ may regulate ECM dynamics through the
synthesis of MMPs and their inhibitors [88]. In this sense,
it has been reported that certain MMPs not only facilitate
collagen degradation, but can also process pro-fibrotic signalling
molecules. Thus MMPs, and hence Mϕ, are likely to contribute
to the degradation of relatively normal ECM structure as well
as facilitate the deposition of a ‘fibrotic’ and dysfunctional
myocardial ECM [21,22]. In fact, fibrotic tissues in general
appear macroscopically pale, reflecting diminished perfusion. As
a result of decreased microvasculature, fibrotic tissues are likely
to contain reduced levels of VEGF and are often chronically
hypoxic, which directly contributes to fibrogenesis through
HIF (hypoxia-inducible factor)-1α-mediated signalling [89].
Accordingly, Mo/Mϕ activate resident endothelial progenitor
cells to form new vessels and this effect seems likely to be
attributable to the paracrine secretion of growth factors and
chemokines [90,91]. As previously stated, although large numbers
of Mϕ accumulate in injured hearts, and are located in close
proximity to matrix-producing myofibroblasts [92], their role in
regulation of the fibrotic response remains unknown. Following
cardiac injury, the complexity of environmental conditions may
result in generation of multiple Mϕ subpopulations with distinct
properties that mediate pro-inflammatory, anti-inflammatory or
fibrogenic actions.
CONCLUSIONS
Although the knowledge of inflammatory pathways has
significantly advanced, many questions involving the role of
Mo/Mϕ in CVD remain unanswered. Indeed, the identification
of the mediators involved in M1/M2 polarization under
physiopathological conditions, and the specific localization of
these cell populations in defined cardiovascular injuries (i.e.
atherosclerosis or MI), requires further characterization. A central
question is whether the deletion of selective Mo populations
will be beneficial or detrimental in certain stages of CVD. New
in vitro and in vivo experimental models may provide a fine tool to
elucidate the biological roles of Mo/Mϕ under physiological and
pathological conditions. Advances in the cardiovascular field are
directed towards elucidating whether pharmacotherapy treatments
may impair the function of these inflammatory myeloid cells or
whether the manipulation of Mo/Mϕ subsets affects the outcome
of these patients. Further progress in this field may help to
develop new pharmacological targets directed to circumvent the
deleterious effects observed in the most common CVD, including
atherosclerosis or MI.
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[Abstract] Calcium is one of the most important intracellular messengers in biological systems. 
Ca
2+
 microfluorimetry is a valuable tool to assess information about mechanisms involved in the 
regulation of intracellular Ca
2+
 levels in research on cells and in living tissues. In essence, the use 
of a dye that fluoresces in the presence of a target substance allows the detection of changes in 
the concentration of this molecule by determining the changes in the fluorescence of the probe 
(increases or decreases, depending on the nature of the dye used; for a review see Tsien et al., 
1985). In this regard, there have been developed two different methodologies to assess 
intracellular Ca
2+
 measurements. On the one hand, ratiometric methods are based on the use of 
a ratio between two fluorescence intensities linked to the physicochemical properties of the probe. 
This allows correction of artifacts due to bleaching, changes in focus, variations in laser intensity, 
etc. but makes measurements and data processing more complicated since they require more 
expensive equipment with the possibility to change the wavelength emission/detection in a rapid 
way. Some ratiometric Ca
2+
 indicators are Fura-2 and Indo-1. On the other hand, on binding to 
Ca
2+
, indicators used for non-ratiometric measurements show a shift in their fluorescence 
intensity (the free indicator has usually a very weak fluorescence). Therefore, although an 
increase in fluorescence signal can be related directly to an increase in Ca
2+
 concentration, the 
fluorescence intensity depends on many factors such as acquisition conditions, probe 
concentration, optical path length, balance between the affinity constants of proteins binding Ca
2+
, 
among others. However, the fluxes of Ca
2+
 are of such a magnitude that these interferences are 
minor contributors to biases in the measurements. There are many non-ratiometric calcium 
indicators, some of which are Fluo-3, Fluo-4 and Calcium-Green-3. Consequently, the most 
suitable Ca
2+
-probe for each experiment will depend on the range of Ca
2+
 concentration that has 
to be evaluated, instrumentation, loading requirements, etc. In the present report we describe the 
protocol employed to quantify intracellular Ca
2+
 changes in peritoneal macrophages using Fura-2 
as a fluorimetric probe and a microfluorimetric protocol that allows quantification of responding 
cells to a given stimulus, localization of the main intracellular domains sensing Ca
2+
 changes and 
a time-resolved analysis of the Fura-2 fluorescence that reflects the intracellular dynamics of Ca
2+
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in these cells (Través et al., 2013).  
 
Materials and Reagents  
 
1. Fura 2-AM (Life Technologies) 
2. DMSO (Sigma-Aldrich) 
3. EGTA 
4. CaCl2 
5. HEPES 
6. Trypan Blue 
7. FCS 
8. Vacuum grease 
9. Peritoneal macrophages obtained from Balb/c male mice (8-12 weeks old) 4 days after i.p. 
administration of 2.5 ml of 3% thioglycollate solution  
Note: In our study (Traves et al., 2013), the effect of prostaglandin E2 on the response to 
P2X/P2Y agonists ATP and BzATP was studied in depth. All these molecules were 
purchased from Sigma-Aldrich (St. Louis, MO). 
10. 10x DPBS without Ca
2+
 Mg
2+
 (Lonza) 
11. Locke's solution (see Recipes) (supplemented with 1 mg/ml BSA)  
 
Equipment  
 
1. Coverslips 0.13-0.16 mm thickness (15 mm of diameter) (SCHOTT AG)  
2. Forceps 
3. 35 mm culture dishes 
4. Basic water-jacket CO2 incubator 
5. Perfusion chamber RC-25F (Warner Instruments) 
6. Valves employed for cell perfusion (Warner Instruments) 
7. Perfusion valves controller VC 8 (Warner Instruments) 
8. Vacuum pump 
9. Water bath 
10. NIKON TE-200 microscope with a Plan Fluor x20/0.5 water objective( Nikon Corporation, 
model:TE-200) 
11. Dichroic mirror (430 nm) and a 510 nm band-pass filter (Omega Optical) 
12. ORCA-ER C4742-80 camera (Hamamatsu Photonics K. K., model: C4742-80)  
13. Filter wheel Lambda 10-2 (Sutter Instrument Company) 
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Software 
 
1. MetaFluor 6.2r & PC software (UNIVERSAL SOLUTIONS) 
 
Procedure  
 
1. Firstly, a sterile coverslip was placed in the bottom of the culture dish (forceps may be 
helpful) where cells stuck from the very beginning. Macrophages were then carefully 
seeded in 1 ml of supplemented Locke's solution at a density of 300,000- 500,000 cells 
per 35 mm culture dish. Since they are non-dividing cells they were used in the following 
two or three days after seeded (likely, after this lapse time, macrophages will be 
completely adhered to coverslips). Extensive washing with 500 μl PBS 1X (three-four 
replicates) was used to ensure that cells were very adherent and alive. The percentage of 
apoptotic/necrotic cells after 3 days in culture was below 5% (determined by using the 
common Trypan Blue staining, see Notes). 
Note: Cell attaching to the coverslip is a critical step in order to perform the 
microfluorimetric analysis. If your plastic or glass interferes with the adherence of the 
macrophages, allow the support to dry with FCS (fetal calf serum) under the cabin to 
improve adherence. Avoid a high density cell culture. A 50-75% subconfluent culture with 
some cells interacting is desirable. 
2. Incubate macrophages in 1 ml supplemented Locke's solution loaded with 5-7 μM Fura-2-
AM (dissolved in DMSO, following the datasheet instructions) for 45 min approximately at 
37 °C. Incubation does NOT involve either shaking or agitation, just a short and slightly 
balancing. 
3. Wash thoroughly the culture monolayer with fresh 500 μl Locke's solution (serum also 
contains esterases that may degrade Fura-2-AM) and place the coverslip in a small 
superfusion chamber (34 µl volume). Junctions between the coverslip and the chamber 
are sealed with vacuum grease. Figure 1 depicts the superfusion chamber apparatus. 
Note: Locke’s media or products perfused to the chamber are regulated using a valve 
system that works by gravity. The perfusion solutions are maintained in a water bath at 
37 °C and the flow rate is kept constant at 1.5 ml/min. The vacuum pump aspires 
continuously the perfusion media after arriving to the chamber to prevent the 
accumulation of the hydrolysis products. 
 Figure 2 shows the experimental setup described here. 
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Figure 1. The superfusion chamber system. In the upper side of the figure, we can 
appreciate the superfusion chamber and the microscope stage. Immediately below these 
two pictures, both pieces are already assembled. The coverslip should be placed in the 
circular hollow remaining in the center. 
 
 
Figure 2. Experimental equipment for Fura-2-AM registers. The temperature and the 
valve controllers, the fluorescence microscope (including its optical filter changer) and the 
necessary equipment to record the fluorescence images (the camera and its controller) 
are depicted above. 
 
4. Images of both control and treated cells are visualized using the Plan Fluor x20/0.5 
objective of the microscope. In this regard, Fura-2-AM has entered the cell and 
intracellular esterases have hydrolyzed the compound providing free Fura-2 that senses 
Ca
2+
 with a high affinity. Fluorescence emission occurs in a broad range around 430 nm 
when the cells are excited at 340 nm. 
Valve 
controller 
Camera controller 
Camera 
Optical Filter 
Changer 
Temperatur
e Controller 
Fluorescen
ce 
Microscop
e 
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Note: In our study (Traves et al., 2013), macrophages were preincubated with different 
prostanoids for at least 10 min and then stimulated for 30 s with a variety of purinergic 
receptor agonists at near-maximal effective concentrations: 100 µM ATP, 100 µM UTP, 10 
µM UDP, 10 µM 2MeSADP, 1,000 µM α,β-meATP or 300 µM BzATP. 
5. Excite cells for 300 ms at 340/380 nm (< 5 ms wavelength change) and select the emitted 
light using the dichroic mirror (430 nm) and a 510-nm band-pass filter. 
Note: The selection of these wavelengths matches with the maximum fluorescence 
registers for Fura-2 calcium-saturated solutions (340 nm) and calcium-free Fura-2 
solutions (380 nm). 
6. Fluorescence images are acquired with the camera every 1.5 seconds and controlled by 
the software. Sampling frequency is 2 Hz. 
 
Data analysis  
 
1. Images are processed by averaging signals from small elliptical regions within individual 
cells (Figure 3). The possibility exists to define specific areas of changes in the 
fluorescence emission (cell contact interactions, protrusions in the cytoplasm –cell 
polarization- or simply cells with different morphologies –round vs. shaped macrophages, 
depending on the treatments-).  
Note: Background signals are subtracted from each wavelength. 
 
 
Figure 3. Metafluor screenshot of cells. ROIs (cells in which a shift in the fluorescence 
emission is recorded as a function of time) and background (normally areas without cells 
or non-responsive cells during the period of observation) are marked with a dot in the 
image. The scale bar on the left side refers to the time variable (in seconds). 
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2. The F340/F380 ratio is calculated on the basis of the initial peak magnitude that 
represents the initial transient components (Figure 4). The F340/F380 ratio is converted 
into a known calcium concentration using the Grynkiewicz equation: 
[Ca
2+
] = Kd * (R – Rmin) / (Rmax – R) * F380max/F380min    (Grynkiewicz et al., 1985) 
Where: 
a. Kd is the dissociation constant (depends on the indicator, but also on pH, ionic 
strength, cell line, etc.). 
b. R is the observed fluorescence ratio at both wavelengths (F340/F380). 
c. Rmin is the minimum ratio value (in absence of Ca
2+
). 
d. Rmax is the maximum ratio value (when Fura-2 is saturated by Ca
2+
). 
e. F380max/F380min is a scaling factor (fluorescence intensity at 380 nm excitation in the 
absence of Ca
2+
 and at Ca
2+
 saturation). 
Note: A calibration curve is required to calculate the Kd value. The F380max and F380min 
values are obtained at the end of each analysis in the same experimental conditions 
(Fura-2-AM concentration, exposition time…). It is based in two calibration points, a 
maximum and a minimum corresponding, respectively, to a saturated calcium solution 
(2.5 mM CaCl2) and a calcium-free solution (containing 10 µM EGTA). Alternatively, 
inhibition of the membrane reticulum Ca
2+
 pump with 200 nM thapsigargin or 500 nM ter-
buthylbenzohydroquinone allow a saturation of the cytoplasmic Ca
2+
 concentration. 
Treatment of cells maintained in extracellular medium lacking or containing Ca
2+
 with a 
low dose of ionomycin (ca. 1 µM) to improve the entrance of the Ca
2+
 into the cell. 
 
 
Figure 4. Fluorescence measured at 340/380 nm. A. Fluorescence intensity at both 
registered excitation wavelengths. B. Registers obtained over the time are divided to 
determine the F340/F380 ratio. 
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Notes 
 
1. Trypan Blue staining can be used to discriminate between viable and non-viable cells. 
The protocol follows these typical steps: 
a. Dilute the cell sample (1:10) to a total volume of 20 µl in a 0.4% Trypan Blue dye 
solution (should be sterile filtered before using).  
b. While non-viable cells will be blue, viable cells will be unstained.  
c. Carefully and continuously fill the hemocytometer chamber with 10 µl of the solution 
each chamber (all hemocytometers consist of two chambers; each is divided into 
nine 1mm
2
 squares).  
d. Count cells under the microscope in four 1 x 1 mm squares of one chamber and 
determine the average number of cells per square. If the cell density is higher than 
200 cells/square, you should dilute your cell suspension.  
e. Total number of particles per ml in the cell sample can be calculated as follows: mean 
number of cells x 1/dilution factor x 10
4
 cells/ml. 
 
Recipes 
 
1. Locke's Solution composition 
140 mM NaCl 
4.7 mM KCl 
2.5 mM CaCl2 
1.2 mM KH2PO4 
1.2 mM MgSO4 
5.5 mM glucose 
10 mM HEPES (pH 7.4)  
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